Abstract
Chapter 3 through Chap. 11 introduces the current status of clinical applications of polypharmacology to disease therapy. This chapter will describe the applications of polypharmacology to drug discovery, mainly from the theoretical account. Specifically, it will explain the theoretical basis for the rational design of new drugs of the “single agent on multiple targets for single disease” category, or the rational design of MTD drugs. Seven essential strategies for MTD drug discovery, including sequence-based epigenetic drugs, sequence-based small-molecule drugs, function-based epigenetic drugs, function-based small-molecule drugs, function-based macromolecule drugs, naturally occurring MTD drugs, and repurposed MTD drugs, will be described in detail with real examples. The contents of this chapter lay the foundation for better understanding of Section II chapters on the methodologies of MTD polypharmacology-based drug discovery and development. Several new concepts on the rational design and discovery of MTDs are proposed by us and presented in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
SoRelle R. Who Owns you DNA? Who Will own it? Circulation. 2000;101:e67–8.
Anderson WF. Human gene therapy. Nature. 1998;392:25–30.
Otsu M, Candotti F. Gene therapy in infants with severe combined immunodeficiency. BioDrugs. 2002;16:229–39.
Baekelandt V, De Strooper B, Nuttin B, et al. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther. 2000;2:540–54.
Galanis E, Russell S. Cancer gene therapy clinical trials: Lessons for the future. Br J Cancer. 2001;85:1432–6.
Tomaselli D, Lucidi A, Rotili D, et al. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev. 2020;40(1):190–244.
Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396–8.
Ledford H. Language: Disputed definitions. Nature. 2008;455(7216):1023–8.
Chandler VL. Paramutation: from maize to mice. Cell. 2007;128(4):641–5.
Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Seminars Reprod Med. 2009;27(5):351–7.
Franci G, Miceli M, Altucci L. Targeting epigenetic networks with polypharmacology: A new avenue to tackle cancer. Epigenomics. 2010;2(6):731–42.
Ptak C, Petronis A. Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Pharmacol Toxicol. 2008;48:257–76.
Ganesan A, Arimondo PB, Rots MG, et al. The timeline of epigenetic drug discovery: From reality to dreams. Clin Epigenetics. 2019;11(1):174.
Heerboth S, Lapinska K, Snyder N, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 2014;6:9–19.
Benedetti R, Conte M, Iside C, et al. Epigenetic-based therapy: From single- to multi-target approaches. Int J Biochem Cell Biol. 2015;69:121–31.
Ganesan A. Multitarget Drugs: An epigenetic epiphany. ChemMedChem. 2016;11(12):1227–41.
de Lera AR, Ganesan A. Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics. 2016;8:105.
Mann BS, Johnson JR, Cohen MH, et al. Approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–52.
Mikaelsson MA, Miller CA. The path to epigenetic treatment of memory disorders. Neurobiol Learn Mem. 2011;96:13–8.
Kaminskas E, Farrell AT, Wang Y-C, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza™) for injectable suspension. Oncologist. 2005;10:176–82.
Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399–409.
Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 2007;5:422–6.
Jamieson AC, Miller JC, Pabo CO. Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov. 2003;2(5):361–8.
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: A new paradigm. Cancer Res. 2017;77(15):3965–81.
Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci. 2009;106:11667–72.
Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–7.
Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167–79.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.
Rupaimoole R, Slack FJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.
Harries LW. RNA biology provides new therapeutic targets for human disease. Front Genet. 2019;10:1–12.
Rani A, O’Shea A, Ianov L, et al. miRNA in circulating microvesicles as biomarkers for age-related cognitive decline. Front Aging Neurosci. 2017;9:1–10.
le Sage C, Lawo S, Cross BCS. CRISPR: A screener’s guide. SLAS Discov. 2020;25(3):233–40.
Jansen R, Van Embden JDA, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75.
Kurata M, Yamamoto K, Moriarity BS, et al. CRISPR/Cas9 library screening for drug target discovery. J Hum Genet. 2018;63:179–86.
Herrera-Carrillo E, Gao Z, Berkhout B. CRISPR therapy towards an HIV cure. Brief Funct Genomics. 2020;19(3):201–8.
Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136:215–33.
Wang Z. MicroRNA-Interference Technologies. Springer-Verlag, Heidelberg, Germany; New York, USA. 2009; ISBN-13: 978-3-642-00488-9.
Wang Z, Luo X, Lu Y, et al. miRNAs at the heart of the matter. J Mol Med. 2008;86:771–3.
Wang Z, Yang B. MicroRNA Expression Detection Methods. Springer-Verlag, Heidelberg, Germany; New York, USA. 2010; ISBN-13: 978-3-642-04927-9.
Friedman RC, Farh KK-H, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
Yang D, Wan X, Dennis AT, et al. MicroRNA biophysically modulates cardiac action potential by direct binding to ion channel. Circulation. 2021;143(16):1597–613.
Bonneau E, Neveu B, Kostantin E, et al. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Ejifcc. 2019;30:114–27.
Lim LP, Lau NC, Garrett-engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;292:288–92.
Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455:64–71.
Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.
Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310:1817–21.
Satoh J, Tabunoki H. Comprehensive analysis of human microRNA target networks. BioData Mining. 2011;4:17.
Li Z, Rana TM. Therapeutic targeting of microRNAs: Current status and future challenges. Nat Rev Drug Discov. 2014;13:622–38.
Alles J, Fehlmann T, Fischer U, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019;47(7):3353–64.
Plotnikova O, Baranova A, Skoblov M. Comprehensive analysis of human microRNA-mRNA interactome. Front Genet. 2019;10:933.
Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol. 2005;3:e85.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.
Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell. 2003;115:787–98.
Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504–11.
Schirle NT, MacRae IJ. The crystal structure of human Argonaute2. Science. 2012;336:1037–40.
Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol. 2006;13:849–51.
Hausser J, Landthaler M, Jaskiewicz L, et al. Relative contribution of sequence and structure features to the mRNA binding of Argonaute/EIF2C-miRNA complexes and the degradation of miRNA targets. Genome Res. 2009;19:2009–20.
Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91–105.
Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39:1278–84.
Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A. 2007;104(45):17719–24.
Glaich O, Parikh S, Bell RE, et al. DNA methylation directs microRNA biogenesis in mammalian cells. Nat Commun. 2019;10(1):5657.
Ivey KN, Muth A, Arnold J, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell. 2008;2:219–29.
Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011;8:376–88.
Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. Nat. Struct. Mol. Biol. 2012;19:321–7.
Rupaimoole R, Calin GA, Lopez-Berestein G, et al. MiRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6:235–46.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.
Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.
Wang Z. MicroRNAs and Cardiovascular Disease. Bentham Science Publishers, Potomac. 2010; eISBN: 978-1-60805-184-7.
Yang B, Lin H, **ao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486–91.
Lu Y, Zhang Y, Wang N, et al. Control of experimental atrial fibrillation by microRNA-328. Circulation. 2010;122:2378–87.
**ao J, Lin H, Luo X, et al. miRNA-605 joins the p53 network to form a p53:miRNA-605:Mdm2 positive feedback loop in response to cellular stress. EMBO J. 2011;30:524–32.
Luo X, Pan Z, Shan H, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939–51.
Zhang S, Yue W, **e Y, et al. The four-microRNA signature identified by bioinformatics analysis predicts the prognosis of nasopharyngeal carcinoma patients. Oncol Rep. 2019;1767–80
Andersen GB, Tost J. Circulating miRNAs as biomarker in cancer. In: Schaffner F, Merlin JL, von Bubnoff N (eds). Tumor liquid biopsies. Volume 215. Springer, Cham. 2020. Recent Results in Cancer Research.
Rooij E, Kauppinen S. Development of micro RNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851–64.
Cavalcante P, Mizrachi T, Barzago C, et al. MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. Pharmacol Res. 2019;148:104388.
Wang Y, Ru J, ** T, et al. An approach to identify individual functional single nucleotide polymorphisms and isoform microRNAs. Biomed Res Int. 2019;2019:6193673.
Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67:7713–22.
Yu F, Yao H, Zhu P, et al. let-7 Regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109–23.
Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–7.
Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: At the crossroads between promises and problems. J Clin Pathol. 2009;62:771–6.
Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, et al. Is miR-34a a well-equipped swordsman to conquer temple of molecular oncology? Chem Biol Drug Des. 2016;87:321–34.
Wang Z. The guideline of the design and validation of miRNA mimics. Methods Mol Biol. 2011;676:211–24.
Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 2008;105:3903–8.
Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7:759–64.
Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA. 2008;14:1834–44.
Bauer M, Kinkl N, Meixner A, et al. Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 2009;16:142–7.
Aagaard LA, Zhang J, von Eije KJ, et al. Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther. 2008;15:1536–49.
Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res. 2008;36:2811–24.
Seyhan AA. A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences. Mol Biosyst. 2016;12(1):295–312.
Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851–64.
Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–84.
Simonson B, Das S. MicroRNA therapeutics: The next magic bullet? Mini Rev Med Chem. 2015;15(6):467–74.
Fiedler J, Batkai S, Thum T. MicroRNA-based therapy in cardiology. Herz. 2014;39(2):194–200.
Mellis D, Caporali A. MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target. Biochem Soc Trans. 2018;46(1):11–21.
Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70(18):7027–30.
Greenberg DS, Soreq H. MicroRNA therapeutics in neurological disease. Curr Pharm Des. 2014;20(38):6022–7.
Singh S, Narang AS, Mahato RI. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res. 2011;28:2996–3015.
Chen Y, Zhao H, Tan Z, et al. Bottleneck limitations for microRNA-based therapeutics from bench to the bedside. Pharmazie. 2015;70:147–54.
Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12:1179–87.
Lal A, Navarro F, Maher CA, et al. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3′UTR microRNA recognition elements. Mol Cell. 2009;35:610–25.
Seitz H. Redefining microRNA targets. Curr Biol. 2009;19:870–3.
Lee YJ, Kim V, Muth DC, et al. Validated microRNA target databases: An evaluation. Drug Dev Res. 2015;76:389–96.
Leclercq M, Diallo AB, Blanchette M. Prediction of human miRNA target genes using computationally reconstructed ancestral mammalian sequences. Nucleic Acids Res. 2017;45:556–66.
Grimm D, Wang L, Lee JS, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Investig. 2010;20:3106–19.
Diederichs S, Jung S, Rothenberg SM, et al. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci USA. 2008;105:9284–9.
McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA. 2008;105:5868–73.
Boudreau RL, Martins I, Davidson BL. Artificial MicroRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and In vivo. Mol Ther. 2009;17:169–75.
Beer S, Bellovin DI, Lee JS, et al. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther. 2010;18:161–70.
Gallant-Behm CL, Piper J, Lynch JM, et al. A microRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Investig Dermatol. 2019;139:1073–81.
Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24:3128–35.
van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–96.
Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31:577.
Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets. 2016;20:737–53.
Misso G, Di Martino MT, De Rosa G, et al. Mir-34: A new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e195.
Ling H, Girnita L, Buda O, et al. Non-coding RNAs: The cancer genome dark matter that matters! Clin Chem Lab Med. 2017;55:705–14.
Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta. 2015;1856:151–64.
Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10:925–33.
Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 2014;9:1932–56.
Wang Kevin C, Chang HY. Molecular mechanisms of long noncoding RNAs. Molecular cell. 2011;43:904–14.
Sanfilippo PG, Hewitt AW. Translating the ENCyclopedia of DNA Elements Project findings to the clinic: ENCODE’s implications for eye disease. Clin Exp Ophthalmol. 2014;42:78–83.
Tragante V, Moore JH, Asselbergs FW. The ENCODE project and perspectives on pathways. Genet Epidemiol. 2014;38:275–80.
Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions Nat Rev Mol Cell Biol. 2021; 22(2): 96–118.
Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genom Proteom Bioinform. 2017;15(3):177–86.
Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs Nat Rev Genet. 2020; 21(2): 102–117.
Zhang Y, Du W, Yang B. Long non-coding RNAs as new regulators of cardiac electrophysiology and arrhythmias: Molecular mechanisms, therapeutic implications and challenges. Pharmacol Ther. 2019;203:107389.
Kim TK, Shiekhattar R. Diverse regulatory interactions of long noncoding RNAs. Curr Opin Genet Dev. 2016;36:73–82.
Zhang Y, Jiao L, Sun L, et al. LncRNA ZFAS1 as a SERCA2a inhibitor to cause intracellular Ca2+ overload and contractile dysfunction in a mouse model of myocardial infarction. Circ Res. 2018;122(10):1354–68.
Ferrè F, Colantoni A, Helmer-Citterich M. Revealing protein-lncRNA interaction. Brief Bioinform. 2016;17(1):106–16.
Long Y, Wang X, Youmans DT, et al. How do lncRNAs regulate transcription? Sci Adv. 2017;3(9):eaao2110.
Jonas K, Calin GA, Pichler M. RNA-binding proteins as important regulators of long non-coding RNAs in cancer. Int J Mol Sci. 2020;21(8):2969.
Prabhakar B, Zhong XB, Rasmussen TP. Exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases. Yale J Biol Med. 2017;90(1):73–86.
Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–61.
Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–509.
Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. Circ Res. 2015;116(4):737–50.
Yu B, Wang S. Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics. 2018;8(13):3654–75.
Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.
Song H, Sun W, Ye G, et al. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11(225):5876.
Hajjari M, Salavaty A. HOTAIR: An oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12(1):1–9.
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.
Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662–74.
Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.
Tang SS, Zheng BY, **ong XD. LincRNA-p21: Implications in human diseases. Int J Mol Sci. 2015;16(8):18732–40.
Jiao L, Li M, Shao Y, Zhang Y, et al. lncRNA-ZFAS1 induces mitochondria-mediated apoptosis by causing cytosolic Ca2+ overload in myocardial infarction mice model. Cell Death Dis. 2019;10(12):942.
Hu F, Shao L, Zhang J, et al. Knockdown of ZFAS1 inhibits hippocampal neurons apoptosis and autophagy by activating the PI3K/AKT pathway via up-regulating miR-421 in epilepsy. Neurochem Res. 2020;45(10):2433–41.
Wu H, Qin W, Lu S, et al. Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2′-O-methylation via NOP58 recruitment in colorectal cancer. Mol Cancer. 2020;19(1):95.
Ishii N, Ozaki K, Sato H, et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51(12):1087–99.
Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014;115:668–77.
Zhu XH, Yuan YX, Rao SL, et al. LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci. 2016;20:3653–60.
Qu X, Du Y, Shu Y, et al. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep. 2017;7:42657.
Zhou X, Zhang W, ** M, et al. lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis. 2017;8:e2929.
Yan B, Yao J, Liu JY, et al. LncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015;116:1143–56.
Sleutels F, Zwart R, Barlow DP. The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature. 2002;415:810–3.
Pandey RR, Mondal T, Mohammad F, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell. 2008;32:232–46.
Novikova IV, Hennelly SP, Sanbonmatsu KY. Sizing up long non-coding RNAs. Do lncRNAs have secondary and tertiary structure? Bioarchitecture. 2012;2(6):189–99.
Sone M, Hayashi T, Tarui H, et al. The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons. J Cell Sci. 2017;120:2498–506.
Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339–46.
Thorenoor N, Faltejskova-Vychytilova P, Hombach S, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622–37.
Liu G, Wang L, Han H, et al. LncRNA ZFAS1 promotes growth and metastasis by regulating BMI1 and ZEB2 in osteosarcoma. Am J Cancer Res. 2017;7(7):1450–62.
Quinn JJ, Ilik IA, Qu K, et al. Revealing long noncoding RNA architecture and functions using domain-specific chromatin isolation by RNA purification. Nat Biotechnol. 2014;32(9):933–40.
Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20(3):300–7.
Zucchelli S, Cotella D, Takahashi H, et al. SINEUPs: A new class of natural and synthetic antisense long non-coding RNAs that activate translation. RNA Biol. 2015;12(8):771–9.
Zucchelli S, Fasolo F, Russo R, et al. SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target proteins in cells. Front Cell Neurosci. 2015;9:174.
Carrieri C, Cimatti L, Biagioli M, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454–7.
Indrieri A, Grimaldi C, Zucchelli S, et al. Synthetic long non-coding RNAs (SINEUPs) rescue defective gene expression in vivo. Sci Rep. 2016;6:27315.
Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.
Vicens Q, Westhof E. Biogenesis of circular RNAs. Cell. 2014;159:13–4.
Zhang XO, Dong R, Zhang Y, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016;26:1277–87.
Panda AC. Circular RNAs act as miRNA sponges. Adv Exp Med Biol. 2018;1087:67–79.
Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.
Salzman J. Circular RNA expression: Its potential regulation and function. Trends Genet. 2016;32:309–16.
Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453–61.
Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870–85.
Gruner H, Cortés-López M, Cooper DA, et al. CircRNA accumulation in the aging mouse brain. Sci Rep. 2016;6:38907.
Westholm JO, Miura P, Olson S, et al. Genome-wide analysis of Drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep. 2014;9:1966–80.
Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019;38(16):e100836.
Guo JU, Agarwal V, Guo H, et al. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15:409.
Hanan M, Soreq H, Kadener S. CircRNAs in the brain. RNA Biol. 2017;14:1028–34.
Bachmayr-Heyda A, Reiner AT, Auer K, et al. Correlation of circular RNA abundance with proliferation–exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci Rep. 2015;5:8057.
Werfel S, Nothjunge S, Schwarzmayr T, et al. Characterization of circular RNAs in human, mouse and rat hearts. J Mol Cell Cardiol. 2016;98:103–7.
Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012;7:e30733.
Denzler R, Agarwal V, Stefano J, et al. Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell. 2014;54:766–76.
Jens M, Rajewsky N, et al. Competition between target sites of regulators shapes post-transcriptional gene regulation. Nat Rev Genet. 2015;16:113–26.
Legnini I, Di Timoteo G, Rossi F, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. 2017;66:22–37.
Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N6-methyladenosine. Cell Res. 2017;27:626–41.
Pamudurti NR, Bartok O, Jens M, et al. Translation of circRNAs. Mol Cell. 2017;66:9–21.
Yang Y, Gao X, Zhang M, et al. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. 2018;110:304–15.
Holdt LM, Stahringer A, Sass K, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14:361–9.
Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;6:2846–58.
Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–65.
Wang Y, Mo Y, Gong Z, et al. Circular RNAs in human cancer. Mol Cancer. 2017;16:25.
Ng WL, Mohd Mohidin TB, Shukla K. Functional role of circular RNAs in cancer development and progression. RNA Biol. 2018;15(8):995–1005.
Floris G, Zhang L, Follesa P, et al. Regulatory role of circular RNAs and neurological disorders. Mol Neurobiol. 2017;54(7):5156–65.
Altesha MA, Ni T, Khan A, et al. Circular RNA in cardiovascular disease. J Cell Physiol. 2019;234(5):5588–600.
Wang T, Pan W, Hu J, et al. Circular RNAs in metabolic diseases. Adv Exp Med Biol. 2018;1087:275–85.
Zeng Y, Zheng Z, Liu F, et al. Circular RNAs in metabolism and metabolic disorders. Obes Rev. 2021;22(7):e13220.
Yang D, Yang K, Yang M. Circular RNA in aging and age-related diseases. Adv Exp Med Biol. 2018;1086:17–35.
Verduci L, Strano S, Yarden Y, et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol. 2019;13(4):669–80.
Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20:1829–42.
Li F, Zhang L, Li W, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget. 2015;6:6001–13.
Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846–58.
Wang Z. Antisense RNA and cancer. In: Cancer and noncoding RNAs by Jaybokas Chakrabarti & Sanga Mitra (eds), Translational epigenetics series. Elsevier AP Academic Press, London. 2017; ISBN: 978-0-12-811022-5.
Katayama S, Tomaru Y, Kasukawa T, et al. Antisense transcript in the mammalian transcriptome. Science. 2005;309:1564–6.
Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013;14(12):880–93.
Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 2009;10(9):637–43.
Piatek MJ, Henderson V, Zynad HS, et al. Natural antisense transcription from a comparative perspective. Genomics. 2016;108(2):56–63.
Wight M, Werner A. The functions of natural antisense transcripts. Essays Biochem. 2013;54:91–101.
Mahmoudi S, Henriksson S, Corcoran M, et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009;33:462–71.
Su WY, Li JT, Cui Y, et al. Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer. Cell Res. 2012;22(9):1374–89.
Galante PA, Vidal DO, de Souza JE, et al. Sense-antisense pairs in mammals: functional and evolutionary considerations. Genome Biol. 2007;8(3):R40.
Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43.
Berteaux N, Aptel N, Cathala G, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol. 2008;28(22):6731–45.
Ling MHT, Ban Y, Wen H, et al. Conserved expression of natural antisense transcripts in mammals. BMC Genomics. 2013;14:243.
Pestka S, Daugherty BL, Jung V, et al. Anti-mRNA: specific inhibition of translation of single mRNA molecules. Proc Natl Acad Sci U S A. 1984;81(23):7525–8.
Munroe SH. Antisense RNA inhibits splicing of pre-mRNA in vitro. EMBO J. 1988;7:2523–32.
Wang Z. The principle of miRNA-Masking antisense oligonucleotides technology. Methods Mol Biol. 2011;676:43–50.
Wang Z. The principle of miRNA-Masking antisense oligonucleotides technology. In MicroRNA and cancer: Methods and protocols by Wei Wu (ed), pp 43–50. Springer-Verlag/Humana Press, New York. 2011; ISBN: 978-1-60761-862-1.
Murakami K, Miyagishi M. Tiny masking locked nucleic acids effectively bind to mRNA and inhibit binding of microRNAs in relation to thermodynamic stability. Biomed Rep. 2014;2(4):509–12.
Ors-Kumoglu G, Gulce-Iz S, Biray-Avci C. Therapeutic microRNAs in human cancer. Cytotechnology. 2019;71(1):411–25.
Gambari R, Brognara E, Spandidos DA, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: nuew trends in the development of miRNA therapeutic strategies in oncology. Int J Oncol. 2016;49(1):5–32.
Zhang S, Yan ML, Yang L, et al. MicroRNA-153 impairs hippocampal synaptic vesicle trafficking via downregulation of synapsin I in rats following chronic cerebral hypoperfusion. Exp Neurol. 2020;332:113389.
Wang N, Sun LY, Zhang SC, et al. MicroRNA-23a participates in estrogen deficiency induced gap junction remodeling of rats by targeting GJA1. Int J Biol Sci. 2015;11(4):390–403.
Duan MJ, Yan ML, Wang Q, et al. Overexpression of miR-1 in the heart attenuates hippocampal synaptic vesicle exocytosis by the posttranscriptional regulation of SNAP-25 through the transportation of exosomes. Cell Commun Signal. 2018;16(1):91.
Zhang T, Hu Y, Ju J, et al. Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Sci Rep. 2016;6:19346.
Hong H, Tao T, Chen S, et al. MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon. Basic Res Cardiol. 2017;112(6):60.
Qiu Y, Cheng R, Liang C, et al. MicroRNA-20b promotes cardiac hypertrophy by the inhibition of mitofusin 2-mediated inter-organelle Ca2+ cross-talk. Mol Ther Nucleic Acids. 2020;19:1343–56.
Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Biotechnology. 1992;24:264–9.
Scott WG, Murray JB, Arnold JR, et al. Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme. Science. 1996;274(5295):2065–9.
Citti L, Rainaldi G. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther. 2005;5(1):11–24.
Phylactou LA, Tsipouras P, Kilpatrick MW. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem Biophys Res Commun. 1998;249(3):804–10.
Beigelman L, McSwiggen JA, Draper KG, et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem. 1995;270(43):25702–8.
Heidenreich O, Benseler F, Fahrenholz A, et al. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem. 1994;269(3):2131–8.
Serganov A, Patel DJ. Ribozymes, riboswitches and beyond: Regulation of gene expression without proteins. Nat Rev Genet. 2007;8(10):776–90.
Pavco PA, Bouhana KS, Gallegos AM, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res. 2000;6(5):2094–103.
Johnston WK, Unrau PJ, Lawrence MS, et al. RNA-catalyzed RNA polymerization: accurate and general RNA-templated primer extension. Science. 292(5520): 1319–25.
de Feyter R, Li P. Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd. Curr Opin Mol Therap. 2000;2(3):332–5.
Khan AU. Ribozyme: a clinical tool Clinica Chimica Acta/Intern J Clin Chem. 2006; 367(1–2): 20–27.
Asha K, Kumar P, Sanicas M, et al. Advancements in nucleic acid based therapeutics against respiratory viral infections. J Clin Med. 2018;8(1):6.
Khanna M, Saxena L, Rajput R, et al. Gene silencing: a therapeutic approach to combat influenza virus infections. Future Microbiol. 2015;10(1):131–40.
Kumar B, Khanna M, Kumar P, et al. Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site. Mol Biotechnol. 2012;51(1):27–36.
Kumar B, Asha K, Khanna M, et al. The emerging influenza virus threat: status and new prospects for its therapy and control. Arch Virol. 2018;163(4):831–44.
Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol. 1996;70(12):8782–91.
Marwick C. First “antisense” drug will treat CMV retinitis. JAMA. 1998; 280 (10): 871.
Hair P, Cameron F, McKeage K. Mipomersen sodium: First global approval. Drugs. 2013;73:487–93.
Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109.
Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637–47.
Dias N, Stein CA. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther. 2002;5:347–55.
Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518–48.
Tanaka M, Nyce JW. Respirable antisense oligonucleotides: A new drug class for respiratory disease. Respir Res. 2001;2:5–9.
Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA. 1978;75:285–8.
Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med. 2005;9:840–53.
Arroyo JD, Gallichotte EN, Tewari M. Systematic design and functional analysis of artificial microRNAs. Nucleic Acids Res. 2014;42(9):6064–77.
Calloni R, Bonatto D. Scaffolds for artificial miRNA expression in animal cells. Hum Gene Ther Methods. 2015;26(5):162–74.
Fowler DK, Williams C, Gerritsen AT, et al. Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer’s guide to potent multi-target RNAi. Nucleic Acids Res. 2016;44(5):e48.
Lebbink RJ, Lowe M, Chan T, et al. Polymerase II promoter strength determines efficacy of microRNA adapted shRNAs. PLoS One. 2011;6:e26213.
Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res. 2006;34:e53.
Yang JS, Maurin T, Robine N, et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci USA. 2010;107:15163–8.
Chen SC, Stern P, Guo Z, et al. Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS One. 2011;6:e22437.
Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9:1327–33.
Grimm D, Wang L, Lee JS, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest. 2010;120:3106–19.
Snove O Jr, Rossi JJ. Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol. 2006;7:231.
Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537–41.
Amendola M, Passerini L, Pucci F, et al. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther. 2009;17:1039–52.
Giering JC, Grimm D, Storm TA, et al. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther. 2008;16:1630–6.
Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA. 2006;103:13759–64.
Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA. 2005;102:13212–7.
Du G, Yonekubo J, Zeng Y, et al. Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J. 2006;273:5421–7.
Hu T, Fu Q, Chen P, et al. Construction of an artificial MicroRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells. Int J Mol Sci. 2009;10:2158–68.
Sun D, Melegari M, Sridhar S, et al. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques. 2006;41:59–63.
Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets. Mol Ther. 2007;15:878–88.
Herrera-Carrillo E, Berkhout B. The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther. 2015;22:485–95.
Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59:75–86.
Wang SL, Yao HH, Qin ZH. Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther. 2009;9:1357–68.
Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun. 2004;316:1050–8.
Fellmann C, Zuber J, McJunkin K, et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell. 2011;41:733–46.
Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods. 2006;3:670–6.
Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326–30.
Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004;32:936–48.
Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406–15.
Kotowska-Zimmer A, Pewinska M, Olejniczak M. Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdiscip Rev RNA. 2021;12(4):e1640.
Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–8.
Passioura T, Gozar MM, Goodchild A, et al. Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnol. 2009;9:57.
Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005;102:13212–7.
Wang J, Theunissen TW, Orkin SH. Site-directed, virus-free, and inducible RNAi in embryonic stem cells. Proc Natl Acad Sci U S A. 2007;104:20850–5.
Zhou HX, **a XG, Xu ZS. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Research. 2005;33:e62.
**a XG, Zhou HX, Xu ZS. Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques. 2006;41:64–8.
Zhu XC, Santa LA, Chang MS, et al. A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs. BMC Molecular Biology. 2007;8:98.
Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–6.
Lu Y, **ao J, Lin H, et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009;37:e24–33.
Wang Z. New concepts of miRNAi technologies. In: MicroRNA interference technologies by Wang Z. Heidelberg: Springer-Verlag; 2009.
Wang Z. The concept of multiple-target anti-miRNA antisense oligonucleotides technology. Methods Mol Biol. 2011;676:51–7.
Wang Z. The concept of multiple-target anti-miRNA antisense oligonucleotides technology. In: Wu W, editor. MicroRNA and cancer. Totowa: Humana Press; 2011.
Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol. 2012;199:407–12.
Umbach JL, Cullen BR. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev. 2009;23:1151–64.
Gebert LFR, Rebhan MAE, Crivelli SEM, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014;42:609–21.
Jopling C. Liver-specific microRNA-122. RNA Biol. 2012;9:137–42.
Jopling CL, Schütz S, Sarnow P. Position-Dependent Function for a Tandem MicroRNA miR-122-Binding Site Located in the Hepatitis C Virus RNA Genome. Cell Host Microbe. 2008;4:77–85.
Baek J, Kang S, Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch Pharm Res. 2014;37:299–305.
Seto AG, Beatty X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183:428–44.
Xu L, Dai WQ, Xu XF, et al. Effects of multiple-target anti-microRNA antisense oligodeoxyribonucleotides on proliferation and migration of gastric cancer cells. Asian Pac J Cancer Prev. 2012;13(7):3203–7.
Subramanian RR, Wysk MA, Ogilvie KM, et al. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers. Nucleic Acids Res. 2015;43(19):9123–32.
Zhou T, Meng X, Che H, et al. Regulation of insulin resistance by multiple miRNAs via targeting the GLUT4 signaling pathway. Cell Physiol Biochem. 2016;38(5):2063–78.
Zaman MS, Maher DM, Khan S, et al. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 2012;5(1):44.
Kolse R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125–40.
Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Therapy. 2011;18:1111–20.
Kurreck J, Wyszko E, Gillen C, et al. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002;30:1911–8.
Seth PP, Siwkowski A, Allerson CR, et al. Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem. 2009;52:10–3.
Stanton R, Sciabola S, Salatto C, et al. Chemical modification study of antisense gapmers. Nucleic Acid Ther. 2012;22:344–59.
Straarup EM, Fisker N, Hedtjärn M, et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 2010;38:7100–11.
Murray S, Ittig D, Koller E, et al. TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues–a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res. 2012;40:6135–43.
Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genet. 2011;43:371–8.
Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides. 2006;16:169–80.
Koller E, Vincent TM, Chappell A, et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011;39:4795–807.
Elmen J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–9.
Rossor AM, Reilly MM, Sleigh JN. Antisense oligonucleotides and other genetic therapies made simple. Pract Neurol. 2018;18:126–31.
Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 1. New York: Marcel Dekker; 2001.
Bennett CF, Baker BF, Pham N, et al. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 2017;57:81–105.
Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307–21.
Lee RG, Crosby J, Baker BF, et al. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res. 2013;6(6):969–80.
Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Nat Acad Sci U S A. 1978;75(1):285–8.
Fortin M, D’Anjou H, Higgins ME, et al. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir Res. 2009;10(1):39.
Burdick AD, Sciabola S, Mantena SR, et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid–modified antisense oligonucleotides. Nucleic Acids Res. 2014;42:4882–91.
Schuster S, Miesen P, van Rij RP. Antiviral RNAi in insects and mammals: Parallels and differences. Viruses. 2019;11:448.
Sharp PA. RNAi and double-strand RNA. Genes Dev. 1999:139–41.
Schwarz DS, Ding H, Kennington L, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006;2:1307–18.
Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57–67.
Grimm D. The dose can make the poison: Lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence. 2011;2:8.
Chakraborty C, Sharma AR, Sharma G, et al. Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine. Mol Ther Nucl Acid. 2017;8:132–43.
Liu YP, Haasnoot J, Berkhout B. Design of extended short hairpin RNAs for HIV-1 inhibition. Nucl Acid Res. 2007;35:5683–93.
Liu YP, von Eije KJ, Schopman NCT, et al. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther. 2009;17:1712–23.
Lam JK, Chow MY, Zhang Y, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
Ren S, Liu Y, Xu W, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190(6):2278–87.
Davis S, Lollo B, Freier S, et al. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34:2294–304.
Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.
Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372:137–41.
Lennox KA, Behlke MA. A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res. 2010;27:1788–99.
Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–9.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198–201.
Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173–8.
Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25:1149–57.
Petrova NS, Chernikov IV, Meschaninova MI, et al. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res. 2012;40:2330–44.
Letsinger RL, Zhang G, Sun DK, et al. Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA. 1989;86:6553–6.
Ligtenberg MA, Pico de Coaña Y, Shmushkovich T, et al. Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. Mol Ther. 2018;26:1482–93.
McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006;24:1005–15.
Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009;27:839–46.
Zhou J, Swiderski P, Li H, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009;37:3094–109.
Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002–7.
Kumar P, Ban HS, Kim SS, et al. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice. Cell. 2008;134:577–86.
Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–17.
Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372(6504):3339–5.
Stein CA, Narayanan R. Antisense oligodeoxynucleotides. Curr Opin Oncol. 1994;6(6):587–94.
Mahato RI, Cheng K, Guntaka RV. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin Drug Deliv. 2005;2(1):3–28.
Ghosh MK, Cohen JS. Oligodeoxynucleotides as antisense inhibitors of gene expression. Prog Nucleic Acid Res Mol Biol. 1992;42:79–126.
Feng J, Wible B, Li GR, et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res. 1997;80(4):572–9.
Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr Med Chem. 2005;12(19):2193–214.
Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther. 2003;99(1):55–77.
Agrawal S, Kandimalla ER. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets. 2001;1(3):197–209.
Bajan S, Hutvagner G. RNA-based therapeutics: From antisense oligonucleotides to miRNAs. Cells. 2020;9(1):137.
Allakhverdi Z, Allam M, Guimond A, et al. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann N Y Acad Sci. 2006;1082:62–73.
Zhang Y, **e X, Ma W, et al. Multi-targeted antisense oligonucleotide delivery by a framework nucleic acid for inhibiting biofilm formation and virulence. Nanomicro Lett. 2020;12(1):74.
Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5(1):48–56.
Hall-Stoodley L, Costerton JW, et al. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108.
Senadheera DB, Cordova M, Ayala EA, et al. Regulation of bacteriocin production and cell death by the VicRK signaling system in Streptococcus mutans. J Bacteriol. 2012;194(6):1307–16.
Dubrac S, Msadek T. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J Bacteriol. 2004;186(4):1175–81.
Senadheera MD, Guggenheim B, Spatafora GA, et al. A VicRK signal transduction system in Streptococcus mutans affects gtfBCD, gbpB, and ftf expression, biofilm formation, and genetic competence development. J Bacteriol. 2005;187(12):4064–76.
Bielinska A, Shivdasani RA, Zhang L, et al. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997–1000.
Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 1995;92:5855–9.
Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997;13:894–9.
Gao H, **ao J, Yang B, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anti-cancer effects. Mol Pharmacol. 2006;70:1621–9.
Wang X, Liu Q, Hou B, et al. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One. 2013;8(9):e73942.
Rad SM, Bamdad T, Sadeghizadeh M, et al. Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy. Tumour Biol. 2015;36(4):2621–9.
Swindell WR, Sarkar MK, Stuart PE, et al. Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin Transl Med. 2015;4:13.
Johari B, Zargan J. Simultaneous targeted inhibition of Sox2-Oct4 transcription factors using decoy oligodeoxynucleotides to repress stemness properties in mouse embryonic stem cells. Cell Biol Int. 2017;41(12):1335–44.
Johari B, Rezaeejam H, Moradi M, et al. Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides. Mol Biol Rep. 2020;47(9):6793–805.
Bigdelou Z, Mortazavi Y, Saltanatpour Z, et al. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells. Mol Biol Rep. 2020;47(3):1859–69.
Tehran MM, Rezaei S, Jalili A, et al. Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment. Drug Discov Today. 2020;25(1):195–200.
Osako MK, Nakagami H, Morishita R. Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy. Curr Top Med Chem. 2012;12(15):1603–7.
Morishita R, Aoki M, Kaneda Y. Decoy oligodeoxynucleotides as novel cardiovascular drugs for cardiovascular disease. Ann N Y Acad Sci. 2001;947:294–301.
Roth M. Transcription factors: Are they a real target for future therapeutic strategies? Pharmacologyonline. 2005;1:45–66.
Morishita R, Aoki M, KanedaY. Decoy oligodeoxynucleotides as novel cardiovascular drugs for cardiovascular disease. Ann NY Acad Sci. 2001;947:294–301.
Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest. 2000;106:1071–5.
Martin TA, Goyal A, Watkins G, et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12:488–96.
Wang LH, Yang XY, Zhang X, et al. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity. Cancer Res. 2003;63:2046–51.
Budhram-Mahadeo V, Ndisang D, Ward T, et al. The Brn-3b POU family transcription factor represses expression of the BRCA-1 antioncogene in breast cancer cells. Oncogene. 1999;18:6684–91.
Tripathi MK. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem. 2005;280:17163–71.
Suzuki YJ, Evans T. Regulation of cardiac myocyte apoptosis by the GATA-4 transcription factor. Life Sci. 2004;74:1829–38.
Kassiri Z, Oudit GY, Sanchez O, et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res. 2005;97:380–90.
Rosati B, Grau F, McKinnon D. Regional variation in mRNA transcript abundance within the ventricular wall. J Mol Cell Cardiol. 2006;40:295–302.
Costantini DL, Arruda EP, Agarwal P, et al. The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell. 2006;23:347–58.
Mohibi S, Chen X, Zhang J. Cancer the ‘RBP’eutics-RNA-binding proteins as therapeutic targets for cancer. Pharmacol Ther. 2019;203:107390.
DeJong ES, Luy B, Marino JP. RNA and RNA-protein complexes as targets for therapeutic intervention. Curr Top Med Chem. 2002;2(3):289–302.
Cheng MS, Su MX, Wang MX, et al. Probes and drugs that interfere with protein translation via targeting to the RNAs or RNA-protein interactions. Methods. 2019;167:124–33.
Baker JD, Uhrich RL, Strovas TJ, et al. Targeting pathological tau by Small molecule inhibition of the Poly(A):MSUT2 RNA-protein interaction. ACS Chem Neurosci. 2020;11(15):2277–85.
Hermann T. Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew Chem Int Ed Engl. 2000;39(11):1890–904.
Baudin F, Bach C, Cusack S, et al. Structure of influenza virus RNP. I. Influenza virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to the solvent. EMBO J. 1994;13(13):3158–65.
Lukong KE, Chang K-W, Khandjian EW, et al. RNA-binding proteins in human genetic disease. Trends Genet. 2008;24(8):416–25.
Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet. 2007;8(7):533–43.
Zhang J, Chen X. Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. Curr Mol Med. 2008;8(8):845–9.
Kechavarzi B, Janga SC. Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome Biol. 2014;15(1):R14.
Neelamraju Y, Gonzalez-Perez A, Bhat-Nakshatri P, et al. Mutational landscape of RNA-binding proteins in human cancers. RNA Biol. 2018;15(1):115–29.
Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: Old players and new actors. Trends Cancer. 2017;3(7):506–28.
Lunde BM, Moore C, Varani G. RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol. 2007;8(6):479–90.
Baltz AG, Munschauer M, Schwanhäusser B, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012;46(5):674–90.
Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149(6):1393–406.
Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15(12):829–45.
Wang ZL, Li B, Luo YX, et al. Comprehensive genomic characterization of RNA-binding proteins across human cancers. Cell Rep. 2018;22(1):286–98.
Hentze MW, Castello A, Schwarzl T, et al. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018;19(5):327–41.
Moore S, Järvelin AI, Davis I, et al. Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer. Curr Opin Genet Dev. 2018;48:112–20.
Bank, RCSB Protein data. RCSB Protein Data Bank-RCSB PDB. Retrieved 2021-08-28.
Lewis BA, Walia RR, Terribilini M, et al. PRIDB: a protein–RNA interface database. Nucleic Acids Res. 2016;39:D277–82.
Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25(5):1069–75.
Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634–44.
Rigo F, Hua Y, Krainer AR, et al. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199(1):21–5.
Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–7.
Mercuri E, Darras BT, Chiriboga CA, et al. CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–35.
Nussbacher JK, Tabet R, Yeo GW, et al. Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron. 2019;102(2):294–320.
Hong DS, Kurzrock R, Oh Y, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011;17(20):6582–91.
Duffy AG, Makarova-Rusher OV, Ulahannan SV, et al. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer. 2016;139(7):1648–57.
Fox RG, Lytle NK, Jaquish DV, et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature. 2016;534(7607):407–11.
Muralidharan R, Babu A, Amreddy N, et al. Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Can Therapeut. 2017;16(8):1470–86.
Jimbo M, Blanco FF, Huang YH, et al. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget. 2015;6(29):27312–31.
Mehta M, Basalingappa K, Griffith JN, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016;7(40):64820–35.
Huang YH, Peng W, Furuuchi N, et al. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res. 2016;76(6):1549–59.
Dong K, Wang R, Wang X, et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat. 2009;113(3):443–56.
Chen H, Liu J, Wang H, et al. Inhibition of RNA-binding protein musashi-1 suppresses malignant properties and reverses paclitaxel resistance in ovarian carcinoma. J Cancer. 2019;10(6):1580–92.
Sheng W, Dong M, Chen C, et al. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Oncotarget. 2017;8(9):14359–73.
Sureban SM, May R, George RJ, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008;134(5):1448–58.
Bai X, Yang C, Jiao L, et al. LncRNA MIAT impairs cardiac contractile function by acting on mitochondrial translocator protein TSPO in a mouse model of myocardial infarction. Signal Transduct Target Ther. 2021;6(1):172.
Mercer JR. Mitochondrial bioenergetics and therapeutic intervention in cardiovascular disease. Pharmacol Ther. 2014;141:13–20.
Morin D, Musman J, Pons S, et al. Mitochondrial translocator protein (TSPO): From physiology to cardioprotection. Biochem Pharmacol. 2016;105:1–13.
Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. Circ RNA Biogenesis competes with Pre-mRNA splicing. Molecular Cell. 2014;56(1):55–66.
Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biology. 2017;14(3):361–9.
Mascini M, Palchetti I, Tombelli S. Nucleic acid and peptide aptamers: Fundamentals and bioanalytical aspects. Angewandte Chemie International Edition. 2012;51(6):1316–32.
Zhou J, Rossi J. Aptamers as targeted therapeutics: Current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202.
Nimjee SM, White RR, Becker RC, et al. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017;57:61–79.
Wu YX, Kwon YJ. Aptamers: The “evolution” of SELEX. Methods. 2016;106:21–8.
Reverdatto S, Burz DS, Shekhtman A. Peptide aptamers: development and applications. Curr Top Med Chem. 2015;15(12):1082–101.
New RRC, Bui TTT, Bogus M. Binding interactions of peptide aptamers. Molecules. 2020;25(24):6055.
Li J, Tan S, Chen X, et al. Peptide aptamers with biological and therapeutic applications. Curr Med Chem. 2011;18(27):4215–22.
Baines IC, Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today. 2006;11(7-8):334–41.
Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, et al. Peptide aptamers: specific inhibitors of protein function. Curr Mol Med. 2004;4(5):529–38.
Crawford M, Woodman R, Ko FP. Peptide aptamers: tools for biology and drug discovery. Brief Funct Genomic Proteomic. 2003;2(1):72–9.
Morita Y, Leslie M, Kameyama H, et al. Aptamer therapeutics in cancer: Current and future. Cancers (Basel). 2018;10(3):80.
Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015;113:78–85.
Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Can Therapeut. 2006;5(12):2957–62.
Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24(1):21.
Song YK, Guo H, Barengo N, et al. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Can Res. 2009;15(13):4336–47.
Lucchesi CA, Zhang J, Ma B, et al. Disruption of the RBM38-eIF4E complex with a synthetic peptide PEP8 increases p53 expression. Can Res. 2019;79(4):807–18.
Zhang J, Cho SJ, Shu L, et al. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev. 2011;25(14):1528–43.
Ebner S, Trieb M, Schönfeld M, et al. Decoy peptides derived from the extracellular domain of toll-like receptor 2 (TLR2) show anti-inflammatory properties. Bioorg Med Chem. 2018;26(16):4615–23.
Piao W, Vogel SN, Toshchakov VY. Inhibition of TLR4 signaling by TRAM-derived decoy peptides in vitro and in vivo. J Immunol. 2013;190(5):2263–72.
Allette Y, Kim Y, Randolph A, et al. Decoy peptide targeted to the Toll-IL-1R domain inhibits LPS and TLR4-active metabolite morphine-3 glucuronide sensitization of sensory neurons. Sci Rep.;7(1): 3741.
Mantovani A, Locati M, Vecchi A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001;22(6):328–36.
Husain M, Becker EJ Jr, Bone NB, et al. NOX2 decoy peptides disrupt trauma-mediated neutrophil immunosuppression and protect against lethal peritonitis. Redox Biol. 2020;36:101651.
Mahjoubin-Tehran M, Rezaei S, Jalili A, et al. Peptide decoys: a new technology offering therapeutic opportunities for breast cancer. Drug Discov Today. 2020;25(3):593–8.
Wu FY, Ou ZL, Feng LY, et al. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res. 2008;6(8):1276–88.
Kwon YJ, Leibovitch BA, Bansal N, et al. Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget. 2016;8(51):88421–36.
Zhang Y, Li D, Zhao X, et al. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Biochem Biophys Res Commun. 2015;463(4):1144–51.
Oh JG, Kim J, Jang SP, et al. Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes. J Mol Cell Cardiol. 2013;56:63–71.
Nabi AN, Biswas KB, Arai Y, et al. Functional characterization of the decoy peptide, [R10P]IFLKRMPSI[19P]. Front Biosci (Elite Ed). 2010;2:1211–7.
Mahjoubin-Tehran M, Rezaei S, Atkin SL, et al. Decoys as potential therapeutic tools for diabetes. Drug Discov Today. 2021;26(7):1669–79.
Ichihara A, Sakoda M, Kurauchi-Mito A, et al. Drug discovery for overcoming chronic kidney disease (CKD): new therapy for CKD by a (pro)renin-receptor-blocking decoy peptide. J Pharmacol Sci. 2009;109(1):20–3.
Chan KK, Tan TJC, Narayanan KK, et al. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. Sci Adv. 2021;7(8):eabf1738.
**g W, Procko E. ACE2-based decoy receptors for SARS coronavirus 2. Proteins. 2021;89(9):1065–78.
Villard S, Piquer D, Raut S, et al. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem. 2002;277(30):27232–9.
Ananyeva NM, Lacroix-Desmazes S, Hauser CA, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis. 2004;15(2):109–24.
Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep. 2014;16(2):398.
Woods AS, Kaminski R, Oz M, et al. Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. J Proteome Res. 2006;5(4):1017–23.
Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS letters. 2013;587:1693–702.
Guo Z, Peng H, Kang J, et al. Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomedical reports. 2016;4:528–34.
Toshchakov VY, Javmen A. Targeting the TLR signalosome with TIR domain-derived cell-permeable decoy peptides: the current state and perspectives. Innate Immun. 2020;26(1):35–47.
Copolovici DM, Langel K, Eriste E, et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972–94.
Kauffman WB, Fuselier T, He J, et al. Mechanism matters: A taxonomy of cell penetrating peptides. Trends Biochem Sci. 2015;40:749–64.
Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157:195–206.
Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug discovery today. 2012;17:850–60.
Järver P, Langel K, El-Andaloussi S, et al. Applications of cell-penetrating peptides in regulation of gene expression. Biochem Soc Trans. 2007;35(Pt 4):770–4.
Toshchakov VY, Vogel SN. Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions. Expert Opinion Biol Therapy. 2007;7:1035–50.
Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013;525(2):162–9.
Brody H. Gene therapy. Nature. 2018;564(7735):S5.
Ylä-Herttuala S. The pharmacology of gene therapy. Mol Ther. 2017;25(8):1731–2.
Tang R, Xu Z. Gene therapy: a double-edged sword with great powers. Mol Cell Biochem. 2020;474(1-2):73–81.
Mullard A. Gene therapy boom continues. Nat Rev Drug Discov. 2019;18(10):737.
Bak RO, Gomez-Ospina N, Porteus MH. Gene editing on center stage. Trends in Genetics. 2018;34(8):600–11.
Memi F, Ntokou A, Papangeli I. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations. Semin Perinatol. 2018;42(8):487–500.
Sanches-da-Silva GN, Medeiros LF, Lima FM. The potential use of the CRISPR-Cas system for HIV-1 gene therapy. Intl J Genom. 2019;2019:8458263.
Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature. 2004;427:779–81.
Kotani H, Kmiec EB. A role for RNA synthesis in homologous pairing events. Mol Cell Biol. 1994;14:6097–106.
Yoon K, Cole-Strauss A, Kmiec EB. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA/DNA oligonucleotide. Proc Natl Acad Sci USA. 1996;93:2071–6.
Andersen MS, Sorensen CB, Bolund L, et al. Mechanisms underlying targeted gene correction using chimeric RNA/DNA and single-stranded DNA oligonucleotides. J Mol Med. 2002;80:770–81.
Leclerc X, Danos O, Scherman D, et al. A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repair. BMC Biotechnol. 2009;9:35.
Liu X, Yan Z, Luo M, et al. Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions. J Virol. 2004;78:4165–75.
Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646–51.
Gruenert DC, Bruscia E, Novelli G, et al. Sequence-specific modification of genomic DNA by small DNA fragments. J Clin Invest. 2003;112:637–41.
Nickerson HD, Colledge WH. A comparison of gene repair strategies in cell culture using a lacZ reporter system. Gene Ther. 2003;10:1584–91.
Bertoni C, Morris GE, Rando TA. Strand bias in oligonucleotide-mediated dystrophin gene editing. Hum Mol Genet. 2005;14:221–33.
Katada H, Komiyama M. Artificial restriction DNA cutters as new tools for gene manipulation. Chembiochem. 2009;10:1279–88.
Miller DG, Wang PR, Petek LM, et al. Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol. 2006;24:1022–6.
Olsen PA, Solhaug A, Booth JA, et al. Cellular responses to targeted genomic sequence modification using single-stranded oligonucleotides and zinc-finger nucleases. DNA Repair (Amst). 2009;8:298–308.
Engstrom JU, Suzuki T, Kmiec EB. Regulation of targeted gene repair by intrinsic cellular processes. Bioessays. 2009;31:159–68.
Igoucheva O, Peritz AE, Levy D, et al. A sequence-specific gene correction by an RNA-DNA oligonucleotide in mammalian cells characterized by transfection and nuclear extract using a lacZ shuttle system. Gene Ther. 1999;6:1960–71.
Radecke S, Radecke F, Peter I, et al. Physical incorporation of a single-stranded oligodeoxynucleotide during targeted repair of a human chromosomal locus. J Gene Med. 2006;8:217–28.
Parekh-Olmedo H, Ferrara L, Brachman E, et al. Gene therapy progress and prospects: targeted gene repair. Gene Ther. 2005;12:639–46.
Maguire KK, Kmiec EB. Multiple roles for MSH2 in the repair of a deletion mutation directed by modified single-stranded oligonucleotides. Gene. 2007;386:107–14.
Pierce EA, Liu Q, Igoucheva O, et al. Oligonucleotide-directed single-base DNA alterations in mouse embryonic stem cells. Gene Ther. 2003;10:24–33.
Dekker M, Brouwers C, te Riele H. Targeted gene modification in mismatch-repair-deficient embryonic stem cells by single-stranded DNA oligonucleotides. Nucleic Acids Res. 2003;31:e27.
Parekh-Olmedo H, Kmiec EB. Progress and prospects: targeted gene alteration (TGA). Gene Ther. 2007;14:1675–80.
Bonner M, Kmiec EB. DNA breakage associated with targeted gene alteration directed by DNA oligonucleotides. Mutat Res. 2009;669:85–94.
Gamper HB Jr, Cole-Strauss A, Metz R, et al. A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry. 2000;39:5808–16.
Cole-Strauss A, Gamper H, Holloman WK, et al. Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. Nucleic Acids Res. 1999;27:1323–30.
Zayed H, McIvor RS, Wiest DL, et al. In vitro functional correction of the mutation responsible for murine severe combined immune deficiency by small fragment homologous replacement. Hum Gene Ther. 2006;17:158–66.
Sangiuolo F, Scaldaferri ML, Filareto A, et al. Cftr gene targeting in mouse embryonic stem cells mediated by Small Fragment Homologous Replacement (SFHR). Front Biosci. 2008;13:2989–99.
Bedayat B, Abdolmohamadi A, Ye L, et al. Sequence-specific correction of genomic hypoxanthine-guanine phosphoribosyl transferase mutations in lymphoblasts by small fragment homologous replacement. Oligonucleotides. 2010;20:7–16.
Gatz SA, Wiesmuller L. p53 in recombination and repair. Cell Death Differ. 2006;13:1003–16.
Tsuchiya H, Harashima H, Kamiya H. Increased SFHR gene correction efficiency with sense single-stranded DNA. J Gene Med. 2005;7:486–93.
Goncz KK, Prokopishyn NL, Abdolmohammadi A, et al. Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells. Oligonucleotides. 2006;16:213–24.
Gruenert DC. Gene correction with small DNA fragments. Curr Res Mol Ther. 1998;1:607–13.
Colosimo A, Guida V, Antonucci I, et al. Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells. Haematologica. 2007;92:129–30.
Todaro M, Quigley A, Kita M, et al. Effective detection of corrected dystrophin loci in mdx mouse myogenic precursors. Hum Mutat. 2007;28:816–23.
Mcnab GL, Ahmad A, Mistry D, et al. Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes. Hum Gene Ther. 2007;18:1171–7.
Sangiuolo F, Filareto A, Spitalieri P, et al. In vitro restoration of functional SMN protein in human trophoblast cells affected by spinal muscular atrophy by small fragment homologous replacement. Hum Gene Ther. 2005;16:869–80.
Consortium TCFGA. World-wide survey of ΔF508 mutation—report from Cystic Fibrosis Genetic Analysis Consortium. Am J Hum Genet. 1990;47:354–7.
Bruscia E, Sangiuolo F, Sinibaldi P, et al. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther. 2002;9:683–5.
Kunzelmann K, Legendre JY, Knoell DL, et al. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther. 1996;3:859–67.
Sangiuolo F, Bruscia E, Serafino A, et al. In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. BMC Med Genet. 2002;3:8.
Knauert MP, Glazer PM. Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet. 2001;10(20):2243–51.
Kuan JY, Glazer PM. Targeted gene modification using triplex-forming oligonucleotides. Methods Mol Biol. 2004;262:173–94.
Hélène C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Des. 1991;6(6):569–84.
Hansen ME, Bentin T, Nielsen PE. High-affinity triplex targeting of double stranded DNA using chemically modified peptide nucleic acid oligomers. Nucleic Acids Res. 2009;37:4498–507.
Chin JY, Glazer PM. Repair of DNA lesions associated with triplex-forming oligonucleotides. Mol Carcinog. 2009;48:389–99.
Lonkar P, Kim KH, Kuan JY, et al. Targeted correction of a thalassemia-associated beta-globin mutation induced by pseudo-complementary peptide nucleic acids. Nucleic Acids Res. 2009;37:3635–44.
Wang G, Seidman MM, Glazer PM. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science. 1996;271:802–5.
Felsenfeld G, Rich A. Studies on the formation of two- and three-stranded polyribonucleotides. Biochim Biophys Acta. 1957;26:457–68.
Kallenbach NR, Daniel WE Jr, Kaminker MA. Nuclear magnetic resonance study of hydrogen-bonded ring protons in oligonucleotide helices involving classical and nonclassical base pairs. Biochemistry. 1976;15:1218–24.
Wang G, Glazer PM. Altered repair of targeted psoralen photo-adducts in the context of an oligonucleotide-mediated triple helix. J Biol Chem. 1995;270:22595–601.
Vasquez KM, Dagle JM, Weeks DL, et al. Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J Biol Chem. 2001;276:38536–41.
Luo Z, Macris MA, Faruqi AF, et al. High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells. Proc Natl Acad Sci U S A. 2000;97:9003–8.
Datta HJ, Glazer PM. Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination. Nucleic Acids Res. 2001;29:5140–7.
Chan PP, Lin M, Faruqi AF, et al. Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. J Biol Chem. 1999;274:11541–8.
Maurisse R, Feugeas JP, Biet E, et al. A new method (GOREC) for directed mutagenesis and gene repair by homologous recombination. Gene Ther. 2002;9:703–7.
Culver KW, Hsieh WT, Huyen Y, et al. Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides. Nat Biotechnol. 1999;17:989–93.
Datta HJ, Chan PP, Vasquez KM, et al. Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J Biol Chem. 2001;276:18018–23.
Goni JR, De La Cruz X, Orozco M. Triplex-forming oligonucleotide target sequences in the human genome. Nucleic Acids Res. 2004;32:354–60.
Simon P, Cannata F, Concordet JP, et al. Targeting DNA with triplex-forming oligonucleotides to modify gene sequence. Biochimie. 2008;90:1109–16.
Chin JY, Kuan JY, Lonkar PS, et al. Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. Proc Natl Acad Sci USA. 2008;105:13514–9.
Nielsen PE. PNA Technology. Mol Biotechnol. 2004;26:233–48.
Bentin T, Nielsen PE. Superior duplex DNA strand invasion by acridine conjugated peptide nucleic acids. J Am Chem Soc. 2003;125:6378–9.
Kim KH, Nielsen PE, Glazer PM. Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids. Nucleic Acids Res. 2007;35:7604–13.
Nielsen PE, Egholm M, Buchardt O. Evidence for (PNA)2/DNA triplex structure upon binding of PNA to dsDNA by strand displacement. J Mol Recognit. 1994;7:165–70.
Yamamoto Y, Yoshida J, Tedeschi T, et al. Highly efficient strand invasion by peptide nucleic acid bearing optically pure lysine residues in its backbone. Nucleic Acids Symp Ser (Oxf). 2006; pp109–10.
Coura RS, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J. 2007;4:99.
Vasileva A, Linden RM, Jessberger R. Homologous recombination is required for AAV-mediated gene targeting. Nucleic Acids Res. 2006;34:3345–60.
Gellhaus K, Cornu TI, Heilbronn R, et al. Fate of recombinant adeno-associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells. Hum Gene Ther. 2010;21:543–53.
Chamberlain JR, Deyle DR, Schwarze U, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther. 2008;16:187–93.
Khan IF, Hirata RK, Wang PR, et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther. 2010;18:1192–9.
Paiboonsukwong K, Ohbayashi F, Shiiba H, et al. Correction of mutant Fanconi anemia gene by homologous recombination in human hematopoietic cells using adeno-associated virus vector. J Gene Med. 2009;11:1012–9.
Mitsui K, Suzuki K, Aizawa E, et al. Gene targeting in human pluripotent stem cells with adeno-associated virus vectors. Biochem Biophys Res Commun. 2009;388:711–7.
Macielag MJ. Chemical properties of antibacterials and their uniqueness. In: Dougherty TJ, Pucci MJ (eds). Antibiotic Discovery and Development. 2012; pp. 801–2.
Ngo HX, Garneau-Tsodikova S. What are the drugs of the future? MedChemComm. 2018;9(5):757–8.
Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004;3(4):301–17.
Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.
Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technol. 2004;1(4):337–41.
Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881–90.
Samanen J. Chapter 5.2 How do SMDs differ from biomolecular drugs? In Ganellin CR, Jefferis R, Roberts SM (eds.). Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies (Kindle ed.). New York: Academic Press. 2013; pp161–203.
Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34.
Usmani SS, Bedi G, Samuel JS, et al. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12(7):e0181748.
Yin W, Rogge M. Targeting RNA: A transformative therapeutic strategy. Clin Transl Sci. 2019;12(2):98–112.
Warner KD, Hajdin CE, Weeks KM. Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018;17(8):547–58.
Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol Rev. 2020;72(4):862–98.
Clamp M. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci USA. 2007;104:19428–33.
Ezkurdia I. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet. 2014;23:5866–78.
Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1:727–30.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5:993–6.
Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol. 2009;13:549–55.
Santos R. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16:19–34.
Sharp PA. The centrality of RNA. Cell. 2009;136:577–80.
Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014;157:77–94.
Djebali S. Landscape of transcription in human cells. Nature. 2012;489:101–8.
Adams BD, Parsons C, Walker L, et al. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127:761–71.
Harrow J. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22:1760–74.
Wilson DN. The A-Z of bacterial translation inhibitors. Crit Rev Biochem Mol Biol. 2009;44:393–33.
Lin J, Zhou D, Steitz TA, et al. Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design. Annu Rev Biochem. 2018;87:451–78.
Donlic A, Hargrove AE. Targeting RNA in mammalian systems with small molecules. Wiley Interdiscip Rev RNA. 2018;9:e1477.
Hermann T. Small molecules targeting viral RNA. Wiley Interdiscip Rev RNA. 2016;7:726–43.
McCown PJ, Corbino KA, Stav S, et al. Riboswitch diversity and distribution. RNA. 2017;23:995–1011.
Cruz JA, Westhof E. The dynamic landscapes of RNA architecture. Cell. 2009;136:604–9.
Butcher SE, Pyle AM. The molecular interactions that stabilize RNA tertiary structure: RNA motifs, patterns, and networks. Acc Chem Res. 2011;44:1302–11.
Jones CP, Ferré-D’Amaré AR. RNA quaternary structure and global symmetry. Trends Biochem Sci. 2015;40:211–20.
Schlick T. Adventures with RNA graphs. Methods. 2018;143:16–33.
Mustoe AM, Busan S, Rice GM, et al. Pervasive regulatory functions of mRNA structure revealed by high-resolution SHAPE probing. Cell. 2018;173:181–95.
Morgan BS, Forte JE, Culver RN, et al. Discovery of key physicochemical, structural, and spatial properties of RNA-targeted bioactive ligands. Angew Chem Int Ed Engl. 2017;56:13498–502.
Morgan BS, Forte JE, Hargrove AE. Insights into the development of chemical probes for RNA. Nucleic Acids Res. 2018;46:8025–37.
Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol. 2014;12:35–48.
Steitz TA. A structural understanding of the dynamic ribosome machine. Nat Rev Mol Cell Biol. 2008;9:242–53.
Lynch SR, Gonzalez RL, Puglisi JD. Comparison of X-ray crystal structure of the 30S subunit-antibiotic complex with NMR structure of decoding site oligonucleotide-paromomycin complex. Structure. 2003;11:43–53.
Fourmy D, Recht MI, Blanchard SC, et al. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science. 1996;274:1367–71.
Demirci H, Murphy F IV, Murphy E, et al. A structural basis for streptomycin-induced misreading of the genetic code. Nat Commun. 2013;4:1355.
Kanazawa H, Baba F, Koganei M, et al. A structural basis for the antibiotic resistance conferred by an N1-methylation of A1408 in 16S rRNA. Nucleic Acids Res. 2017;45:12529–35.
Kondo J. A structural basis for the antibiotic resistance conferred by an A1408G mutation in 16S rRNA and for the antiprotozoal activity of aminoglycosides. Angew Chem Int Ed Engl. 2012;51:465–8.
Zhang X, Lai M, Chang W, et al. Structures and stabilization of kinetoplastid-specific split rRNAs revealed by comparing leishmanial and human ribosomes. Nat Commun. 2016;7:13223.
Myasnikov AG, Kundhavai Natchiar S, et al. Structure-function insights reveal the human ribosome as a cancer target for antibiotics. Nat Commun. 2016;7:12856.
Di Giorgio A, Duca M. Synthetic small-molecule RNA ligands: future prospects as therapeutic agents. MedChemComm. 2019;10:1242–55.
Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev. 2006;26:595–625.
Kulinski T, Olejniczak M, Huthoff H, et al. The apical loop of the HIV-1 TAR RNA hairpin is stabilized by a cross-loop base pair. J Biol Chem. 2003;278:38892–901.
Le Grice SF. Targeting the HIV RNA genome: high-hanging fruit only needs a longer ladder. Curr Top Microbiol Immunol. 2015;389:147–69.
Connelly CM, Moon MH, Schneekloth JS., Jr. The emerging role of RNA as a therapeutic target for small molecules. Cell Chem Biol. 2016; 23:1077–1090.
Stelzer AC, Frank AT, Kratz JD, et al. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat Chem Biol. 2011;7:553–9.
Dibrov SM, Parsons J, Carnevali M, et al. Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site. J Med Chem. 2014;57:1694–707.
Plant EP, Pérez-Alvarado GC, Jacobs JL, et al. A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal. PLoS Biol. 2005;3:e172.
Su MC, Chang CT, Chu CH, et al. An atypical RNA pseudoknot stimulator and an upstream attenuation signal for -1 ribosomal frameshifting of SARS coronavirus. Nucleic Acids Res. 2005;33:4265–75.
Park SJ, Kim YG, Park HJ. Identification of RNA pseudoknot-binding ligand that inhibits the -1 ribosomal frameshifting of SARS-coronavirus by structure-based virtual screening. J Am Chem Soc. 2011;133:10094–100.
Ritchie DB, Soong J, Sikkema WK, et al. Anti-frameshifting ligand reduces the conformational plasticity of the SARS virus pseudoknot. J Am Chem Soc. 2005;136:2196–9.
Tucker BJ, Breaker RR. Riboswitches as versatile gene control elements. Curr Opin Struct Biol. 2005;15:342–8.
Hallberg ZF, Su Y, Kitto RZ, et al. Engineering and in vivo applications of riboswitches. Annu Rev Biochem. 2017;86:515–39.
Chauvier A, Picard-Jean F, Berger-Dancause JC, et al. Transcriptional pausing at the translation start site operates as a critical checkpoint for riboswitch regulation. Nat Commun. 2017;8:13892.
Lee ER, Blount KF, Breaker RR. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol. 2009;6:187–94.
Winkler WC, Cohen-Chalamish S, Breaker RR. An mRNA structure that controls gene expression by binding FMN. Proc Natl Acad Sci USA. 2002;99:15908–13.
Serganov A, Nudler E. A decade of riboswitches. Cell. 2013;152:17–24.
Zhang R, Ou HY, Zhang CT. DEG: a database of essential genes. Nucleic Acids Res. 2004;32:D271–2.
Serganov A, Huang L, Patel DJ. Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. Nature. 2009;458:233–7.
Howe JA, Wang H, Fischmann TO, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015;526:672–7.
Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci. 2017;8:1–6.
Aartsma-Rus A, Krieg AM. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 2017;27:1–3.
Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345:688–93.
Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61:6501–17.
Sturm S, Günther A, Jaber B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85:181–93.
Palacino J, Swalley SE, Song C, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015;11:511–7.
Cheung AK, Hurley B, Kerrigan R, et al. Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61:11021–36.
Velagapudi SP, Gallo SM, Disney MD. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol. 2014;10:291–7.
Velagapudi SP, Cameron MD, Haga CL, et al. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci USA. 2016;113:5898–903.
Li Y, Disney MD. Precise small molecule degradation of a noncoding RNA identifies cellular binding sites and modulates an oncogenic phenotype. ACS Chem Biol. 2018;13:3065–71.
Costales MG, Hoch DG, Abegg D, Childs-Disney JL, Velagapudi SP, Adibekian A, Disney MD. (2019a) A designed small molecule inhibitor of a non-coding RNA sensitizes HER2 negative cancers to herceptin. J Am Chem Soc. 2019;141:2960–74.
Costales MG, Haga CL, Velagapudi SP, et al. Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit. J Am Chem Soc. 2017;139:3446–55.
Costales MG, Suresh B, Vishnu K, et al. Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA. Cell Chem Biol. 2019;26:1180–6.
Velagapudi SP, Costales MG, Vummidi BR, et al. Approved anti-cancer drugs target oncogenic non-coding RNAs. Cell Chem Biol. 2018;25:1086–94.e7.
Brown JA, Bulkley D, Wang J, et al. Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. Nat Struct Mol Biol. 2014;21(7):633–40.
Pedram Fatemi R, Salah-Uddin S, Modarresi F, et al. Screening for small-molecule modulators of long noncoding RNA-protein interactions using AlphaScreen. J Biomol Screen. 2015;20(9):1132–41.
Fatemi RP, Velmeshev D, Faghihi MA. De-repressing LncRNA-targeted genes to upregulate gene expression: Focus on small molecule therapeutics. Mol Ther Nucleic Acids. 2014;3:e196.
Bennett CF, Swayze EE. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50(1):259–93.
Simone R, Balendra R, Moens TG, et al. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med. 2018;10:22–31.
Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83:1043–50.
Disney MD, Liu B, Yang WY, et al. A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem Biol. 2012;7:1711–8.
Qurashi A, Liu H, Ray L, et al. Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila. Hum Mol Genet. 2012;21:2068–75.
Green KM, Sheth UJ, Flores BN, et al. High-throughput screening yields several small-molecule inhibitors of repeat-associated non-AUG translation. J Biol Chem. 2019;294:18624–38.
Parkesh R, Childs-Disney JL, Nakamori M, et al. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc. 2012;134:4731–42.
Angelbello AJ, Rzuczek SG, Mckee KK, et al. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model. Proc Natl Acad Sci USA. 2019;116:7799–804.
Rzuczek SG, Colgan LA, Nakai Y, et al. Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nat Chem Biol. 2017;13:188–93.
Miglietta G, Cogoi S, Marinello J, et al. RNA G-quadruplexes in Kirsten Ras (KRAS) oncogene as targets for small molecules inhibiting translation. J Med Chem. 2017;60:9448–61.
Katsuda Y, Sato S, Asano L, et al. A small molecule that represses translation of G-quadruplex-containing mRNA. J Am Chem Soc. 2016;138:9037–40.
Zhang P, Park HJ, Zhang J, et al. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA. Proc Natl Acad Sci USA. 2020;117:1457–67.
Liang X-H. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat Biotechnol. 2016;34:875–80.
Liang X-H. Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels. Nucleic Acids Res. 2017;45:9528–46.
Fellmann C, Gowen BG, Lin P-C, et al. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16:89–100.
Childs-Disney JL, Disney MD. Approaches to validate and manipulate RNA targets with small molecules in cells. Annu Rev Pharmacol Toxicol. 2016;56:123–40.
Wakelin LP. Polyfunctional DNA intercalating agents. Med Res Rev. 1986;6:275–340.
Costales MG, Childs-Disney JL, Haniff HS, et al. How we think about targeting RNA with small molecules. J Med Chem. 2020;63(17):8880–900.
Chaires JB. Drug-DNA interactions. Curr Opin Struc Biol. 1998;8:314–20.
Graves DE. Targeting DNA through-covalent interactions of reversible binding drugs. Methods Enzymol. 2001;340:377–95.
Rehman SU, Sarwar T, Husain MA, et al. Studying non-covalent drug-DNA interactions. Arch Biochem Biophys. 2015;576:49–60.
Strekowski L, Wilson B. Noncovalent interactions with DNA: an overview. Mutat Res. 2007;623(1-2):3–13.
Turner PR, Denny WA. The genome as a drug target: sequence specific minor groove binding ligands. Curr Drug Targ. 2000;1:1–14.
Geierstanger BH, Wemmer DE. Complexes of the minor groove of DNA. Annu Rev Biophys Biomol Struct. 1995;24:463–93.
Reddy BS, Sondhi SM, Lown JW. Synthetic DNA minor groove-binding drugs. Pharmacol Ther. 1999;84:1–111.
Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol. 2003;13:284–99.
Neidle S. Structural aspects of drug-DNA complexes: molecular modelling of intercalative interactions. Drugs Exp Clin Res. 1986;12(6-7):455–62.
Trotta E, D’Ambrosio E, Ravagnan G, et al. Evidence for DAPI intercalation in CG sites of DNA oligomer [d(CGACGTCG)]2: a 1H NMR study. Nucleic Acids Res. 1995;23(8):1333–40.
Dziegielewski J, Slusarski B, Konitz A, et al. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol. 2002;63(9):1653–62.
Misra VK, Honig B. On the magnitude of the electrostatic contribution to ligand-DNA interactions. Proc Nat Acad Sci USA. 1995;92:4691–5.
Manning GS. The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides. Q Rev Biophys. 1978;11:179–246.
Dogra S, Awasthi P, Tripathi S, et al. NMR-based structure of anticancer drug mitoxantrone stacked with terminal base pair of DNA hexamer sequence d-(ATCGAT)2. J Biomol Struct Dyn. 2014;32(7):1164–83.
Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.
Holliday R. Epigenetics: A historical overview. Epigenetics. 2006;1(2):76–80.
Lorch Y, Maier-Davis B, Kornberg RD. Mechanism of chromatin remodeling. PNAS. 2010;107(8):3458–62.
Lorch Y, Kornberg RD. Chromatin-remodeling for transcription. Q Rev Biophys. 2017;50:e5.
Kaur J, Daoud A, Eblen ST. Targeting chromatin remodeling for cancer therapy. Curr Mol Pharmacol. 2019;12(3):215–29.
Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81–92.
Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18(9):517–34.
Mirfattah B, Herring J, Tang H, et al. Probes and targets of DNA methylation and demethylation in drug development. Curr Top Med Chem. 2017;17(15):1727–40.
Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472–9.
Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14(6):341–56.
Lu X, Zhao BS, He C. TET family proteins: oxidation activity, interacting molecules, and functions in diseases. Chem Rev. 2015;115(6):2225–39.
Bannister AJ, Zegerman P, Partridge JF, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001;410(6824):120–4.
Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–5.
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–52.
Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81–120.
Schneider A, Chatterjee S, Bousiges O, et al. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics. 2013;10(4):568–88.
Wang Y, Miao X, Liu Y, et al. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxid Med Cell Longev. 2014;2014:641979.
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19–25.
Benedetti R, Conte M, Altucci L. Targeting Histone deacetylases in diseases: Where are we? Antioxid Redox Signal. 2015;23(1):99–126.
Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26(10):880–9.
McCabe MT, Mohammad HP, Barbash O, et al. Targeting Histone methylation in cancer. Cancer J. 2017;23(5):292–301.
Yi X, Jiang X, Li X, et al. Histone lysine methylation and congenital heart disease: From bench to bedside. Int J Mol Med. 2017;40(4):953–64.
Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics. 2010;2(5):657–6.
Du J, Johnson LM, Jacobsen SE, et al. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015;16(9):519–32.
Michalak EM, Burr ML, Bannister AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 2019;20(10):573–89.
Richart L, Margueron R. Drugging histone methyltransferases in cancer. Curr Opin Chem Biol. 2020;56:51–62.
Liu Q, Wang MW. Histone lysine methyltransferases as anti-cancer targets for drug discovery. Acta Pharmacol Sin. 2016;37(10):1273–80.
Blanc RS, Richard S. Arginine methylation: The coming of age. Mol Cell. 2017;65(1):8–24.
Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20(10):642–57.
Cha B, Jho EH. Protein arginine methyltransferases (PRMTs) as therapeutic targets. Expert Opin Ther Targets. 2012;16(7):651–64.
Zhang J, **g L, Li M, et al. Regulation of histone arginine methylation/demethylation by methylase and demethylase. Mol Med Rep. 2019;19(5):3963–71.
Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20(12):1394–6.
Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73(10):2936–42.
Maiques-Diaz A, Somervaille TC. LSD1: biologic roles and therapeutic targeting. Epigenomics. 2016;8(8):1103–16.
Harmeyer KM, Facompre ND, Herlyn M, et al. JARID1 histone demethylases: Emerging targets in cancer. Trends Cancer. 2017;3(10):713–25.
Niu Y, Zhao X, Wu YS, et al. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteom Bioinform. 2013;11(1):8–17.
Frye M, Harada BT, Behm M, et al. RNA modifications modulate gene expression during development. Science. 2018;361(6409):1346–9.
Cantara WA, Crain PF, Rozenski J, et al. The RNA modification database, RNAMDB: 2011 update. Nucleic Acids Res. 2011;39:D195–201.
Czerwoniec A, Dunin-Horkawicz S, Purta E, et al. MODOMICS: a database of RNA modification pathways 2008 update. Nucleic Acids Res. 2009;37:D118–21.
Narayan P, Rottman FM. Methylation of mRNA. Adv Enzymol Relat Areas Mol Biol. 1992;65:255–85.
Adams JM, Cory S. Modified nucleosides and bizarre 5′-termini in mouse myeloma mRNA. Nature. 1975;255:28–33.
Desrosiers RC, Friderici KH, Rottman FM. Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5′ terminus. Biochemistry. 1975;14:4367–74.
Canaani D, Kahana C, Lavi S, et al. Identification and map** of N6-methyladenosine containing sequences in simian virus 40 RNA. Nucleic Acids Res. 1979;6:2879–99.
Chen-Kiang S, Nevins JR, Darnell JE Jr. N-6-methyl-adenosine in adenovirus type 2 nuclear RNA is conserved in the formation of messenger RNA. J Mol Biol. 1979;135:733–52.
Traube FR, Carell T. The chemistries and consequences of DNA and RNA methylation and demethylation. RNA Biol. 2017;14(9):1099–107.
Chen X, Sun YZ, Liu H, et al. RNA methylation and diseases: experimental results, databases, Web servers and computational models. Brief Bioinform. 2019;20(3):896–917.
Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635–46.
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.
Chen XY, Zhang J, Zhu JS. The role of m6A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103.
Zhao W, Qi X, Liu L, et al. Epigenetic regulation of m6A modifications in human cancer. Mol Ther Nucleic Acids. 2020;19:405–12.
Qin Y, Li L, Luo E, et al. Role of m6A RNA methylation in cardiovascular disease. Int J Mol Med. 2020;46(6):1958–72.
Zeng C, Huang W, Li Y, et al. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13(1):117.
Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 2019;12(1):121.
Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6a mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.
Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018;69(6):1028–38.
Patil DP, Chen CK, Pickering BF, et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–73.
Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93–5.
Mendel M, Chen KM, Homolka D, et al. Methylation of structured RNA by the m6A writer METTL16 is essential for mouse embryonic development. Mol Cell. 2018;71(6):986–1000.
Warda AS, Kretschmer J, Hackert P, et al. Human METTL16 is a N6-methyladenosine (m6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017;18(11):2004–14.
Pendleton KE, Chen B, Liu K, et al. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(5):824–35.
Ignatova VV, Stolz P, Kaiser S, et al. The rRNA m6A methyltransferase METTL5 is involved in pluripotency and developmental programs. Genes Dev. 2020;34(9-10):715–29.
van Tran N, Ernst FGM, Hawley BR, et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 2019;47(15):7719–33.
Pinto R, Vagbo CB, Jakobsson ME, et al. The human methyltransferase ZCCHC4 catalyses N6-methyladenosine modification of 28S ribosomal RNA. Nucleic Acids Res. 2020;48(2):830–46.
Ren W, Lu J, Huang M, et al. Structure and regulation of ZCCHC4 in m6A-methylation of 28S rRNA. Nat Commun. 2019;10(1):5042.
Ma H, Wang X, Cai J, et al. N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat Chem Biol. 2019;15(1):88–94.
Blanquart C, Linot C, Cartron PF, et al. Epigenetic metalloenzymes. Curr Med Chem. 2019;26(15):2748–85.
Zwergel C, Valente S, Jacob C, et al. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opin Drug Discov. 2015;10(6):599–613.
Faria Freitas M, Cuendet M, Bertrand P. HDAC inhibitors: A 2013–2017 patent survey. Expert Opin Ther Pat. 2018;1–17
Yang XF, Zhao ZJ, Liu JJ, et al. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study. Oncotarget. 2017;8(2):3156–69.
Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659–71.
Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828–35.
Gore SD. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol. 2005; 2 Suppl1: S30–S35.
Berry DH, Fernbach DJ, Herson J, et al. Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: A Southwest Oncology Group Study. Cancer. 1980;46(5):1098–103.
Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
Han T, Zhuo M, Hu H, et al. Synergistic effects of the combination of 5-Aza-CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Oncol Rep. 2018;39(1):264–70.
Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One. 2010;5(7):e11457.
Paul B, Li Y, Tollefsbol TO. The Effects of combinatorial genistein and sulforaphane in breast tumor inhibition: Role in epigenetic regulation. Int J Mol Sci. 2018;19(6):1754.
Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27.
Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010;17(9):1144–51.
Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010;107(33):14639–44.
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.
Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–25.
D’Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–36.
Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917–27.
Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud. 2018;4(2):a001578.
Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523–43.
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81.
Wang DF, Helquist P, Wiech NL, et al. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem. 2005;48(22):6936–47.
Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des. 2008;14(6):505–28.
Rotili D, Tomassi S, Conte M, et al. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem. 2014;57(1):42–55.
Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5(10):981–9.
Inoue S, Riley J, Gant TW, et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 2007;21(8):1773–82.
Zang L, Kondengaden SM, Zhang Q, et al. Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors. Oncotarget. 2017;8(38):63187–207.
Kargbo RB. Histone deacetylase inhibitors as treatment for targeting multiple components in cancer therapy. ACS Med Chem Lett. 2018;9(3):167–8.
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82.
Li YH, Yu CY, Li XX, et al. Therapeutic target database update 2018: Enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 2018;46:D1121–7.
Gaulton A, Hersey A, Nowotka M, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45:D945–54.
Kim S, Thiessen PA, Bolton EE, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.
Gilson MK, Liu T, Baitaluk M, et al. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res. 2016;44:D1045–53.
Günther S, Kuhn M, Dunkel M, et al. SuperTarget and matador: Resources for exploring drug-target relationships. Nucleic Acids Res. 2008;36:D919–22.
Yıldırım MA, Goh K-I, Cusick ME, et al. Drug—target network. Nat Biotechnol. 2007;25:1119–26.
Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012;8:e1002503.
Lu J-J, Pan W, Hu Y-J, et al. Multi-target drugs: The trend of drug research and development. PLoS One. 2012;7:e40262.
Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discovery. 2016;16:19–34.
Hert KMJ, Irwin JJ, et al. Quantifying the Relationships among Drug Classes. J Chem Inf Model. 2008;48:755–65.
Shi D, Khan F, Abagyan R. Extended multitarget pharmacology of anticancer drugs. J Chem Inf Model. 2019;59(6):3006–17.
He S, Dong G, Wu S, et al. Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): Discovery of novel multitargeting antitumor agents. J Med Chem. 2018;61(16):7245–60.
Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31(12):2235–46.
Zhao H, Dietrich J. Privileged scaffolds in lead generation. Expert Opin Drug Discov. 2015;10(7):781–90.
Silva CFM, Pinto DCGA, Silva AMS. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer’s disease. Expert Opin Drug Discov. 2018;13(12):1141–51.
Faheem, Karan Kumar B, Venkata Gowri Chandra Sekhar K, et al. 1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design Expert Opin Drug Discov. 2021: 16(10): 1119–1147.
Liargkova T, Eleftheriadis N, Dekker F, et al. Small multitarget molecules incorporating the enone moiety. Molecules. 2019;24(1):199.
Gupta D, Jaina DK, Trivedi P. Recent advances in chalcones as antiinfective agents. Int J Chem Sci. 2010;8:649–54.
Sinha S, Medhi B, Sehga R. Chalcones as an emerging lead molecule for antimalarial therapy: A review. J Mod Med Chem. 2013;1:64–77.
Yadav VR, Prasad S, Sung B, et al. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol. 2011;11:295–309.
Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem. 2007;42:125–37.
Katsori AM, Hadjipavlou-Litina D. Recent progress in therapeutic applications of chalcones. Expert Opin Ther Pat. 2011;21:1575–96.
Rahman MA. Chalcone: A valuable insight into the recent advances and potential pharmacological activities. Chem Sci J. 2011;29:1–16.
Di Carlo G, Mascolo N, Izzo AA, et al. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci. 1999;65:337–53.
Nasir S, Bukhari A, Jasamai M, et al. Synthesis and biological evaluation of chalcone derivatives (mini review). Med Chem. 2012;12:1394–403.
Eddarir S, Cotelle N, Bakkour Y, et al. An efficient synthesis of chalcones based on the Suzuki reaction. Tetrahedron Lett. 2003;44:5359–63.
Dhar DN. Chemistry of chalcones and related compounds. John Wiley & Sons, Inc.; New York, NY, USA: 1981; pp213.
Guida A, Lhouty MH, Tichit D, et al. Hydrotalcites as base catalysts. Kinetics of Claisen-Schmidt condensation, intramolecular condensation of acetonylacetone and synthesis of chalcone. Appl Catal A. 1997;164:251–64.
Romanelli G, Pasquale G, Sathicq A, et al. Synthesis of chalcones catalyzed by aminopropylated silica sol–gel under solvent-free conditions. J Mol Catal A Chem. 2011;340:24–32.
Kamboj S, Singh R. Chromanone-A prerogative therapeutic scaffold: An overview. Arab J Sci Eng. 2021: 1–37.
Emami S, Ghanbarimasir Z. Recent advances of chroman-4-one derivatives: synthetic approaches and bioactivities. Eur J Med Chem. 2015;93:539–63.
Panche AN, Diwan AD, Chandra R. Flavonoids: an overview. J Nutr Sci. 2016;5(47):1–15.
Christophe Carola H, Ralf Rosskopf M. Use of chroman-4-one derivatives. United States Patent application publication. US 2010/0028278 A1,1, 1–24 (2010).
Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem. 2001;I(2001):569–90.
Park JH, Lee SU, Kim SH, et al. Chromone and chromanone derivatives as strand transfer inhibitors of HIV-1 integrase. Arch Pharm Res. 2008;31(1):1–5.
Jalili-Baleh L, Babaei E, Abdpour S, et al. A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer’s disease. Eur J Med Chem. 2018;152:570–89.
Stefanachi A, Leonetti F, Pisani L. Coumarin: A natural, privileged and versatile scaffold for bioactive compounds. Molecules. 2018;23(2):250.
Vogel A. Darstellung von Benzoesaure aus der Tonka-Boline und aus den MeliIoten-oder Steinklee-Blumen. Ann Phys. 1820;64:161–6.
Dean FM. Naturally occurring coumarins. Fortschr Chem Org Naturst IX. 1952;9:225–91.
Murray RDH, Mendez J, Brown SA. The Natural coumarins: Occurrence, chemistry and biochemistry. New York, NY, USA: John Wiley & Sons; 1982.
Murray RDH. Naturally occurring plant coumarins. Fortschr Chem Org Naturst. 1991;58:84–322.
O’Kennedy R. Thornes RD (eds). Biology, applications, and mode of action. John Wiley & Sons, New York, NY, USA: Coumarins; 1997.
Mzezewa SC, Omoruyi SI, Zondagh LS, et al. Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer’s disease agents. J Enzyme Inhib Med Chem. 2021;36(1):1607–21.
Jameel E, Umar T, Kumar J, et al. Coumarin: A privileged scaffold for the design and development of antineurodegenerative agents. Chem Biol Drug Des. 2016;87(1):21–38.
Detsi A, Kontogiorgis C, Hadjipavlou-Litina D. Coumarin derivatives: An updated patent review (2015–2016). Expert Opin Ther Pat. 2017;27:1201–27.
Barot KP, Jain SV, Kremer L, et al. Recent advances and therapeutic journey of coumarins: Current status and perspectives. Med Chem Res. 2015;24:2771–98.
Uto Y. 1, 2-Benzisoxazole: A privileged structure with a potential for polypharmacology. Curr Pharm Des. 2016;22(21):3201–11.
Rakesh KP, Shantharam CS, Sridhara MB. Benzisoxazole: a privileged scaffold for medicinal chemistry. Medchemcomm. 2017;8(11):2023–39.
Kirk KL, Filler R. In Biomedical frontiers of fluorine chemistry, symposium series. American Chemical Society, Washington, DC. 1996; vol. 639: pp 1–24.
Gelders YG, Heylen SLE, Vander BG, et al. Pilot clinical investigation of risperidone in the treatment of psychotic patients. J Pharmacopsychiatry. 1990;23:206–11.
Dollery C. Therapeutic drugs. Edinburgh, UK: Churchill Livingstone; 1999.
Park BK, Kitteringham NR. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab Rev. 1994;26:605–43.
Deng BL, Cullen MD, Zhou Z, et al. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. Bioorg Med Chem. 2006;14:2366–74.
Chaker A, Najahi E, Chatriant O, et al. New 3-substituted-2,1-benzisoxazoles: synthesis and antimicrobial activities. Arab J Chem. 2017;10:S2464–70.
Sivala MR, Chintha V, Potla KM, et al. In silico docking studies and synthesis of new phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole as potential antimicrobial agents. J Recept Signal Transduct. 2020;40:1–7.
Shivaprasad CM, Jagadish S, Swaroop TR, et al. Synthesis of new benzisoxazole derivatives and their antimicrobial, antioxidant and anti-inflammatory activities. Eur J Chem. 2014;5:91–5.
Wierenga W, Evans BR, Zurenko GE. Benzisoxazolones: antimicrobial and antileukemic activity. J Med Chem. 1984;27:1212–5.
Hrib NJ, Jurcak JG, Burgher KL, et al. Benzisoxazole- and benzisothiazole-3-carboxamides as potential atypical antipsychotic agents. J Med Chem. 1994;37:2308–14.
Davis L, Effland RC, Klein JT, et al. 3-substituted-1,2-benzisoxazoles: Novel antipsychotic agents. Drug Des Disco. 1992;8:225–40.
Saunders JC, Williamson WRN. Potential antiinflammatory compounds. 2. Acidic antiinflammatory 1,2-benzisoxazoles. J Med Chem. 1979;22:1554–8.
Khedekar P, Bahekar R, Chopadec R, et al. Synthesis and anti-inflammatory activity of alkyl/arylidene-2-aminobenzothiazoles and 1-benzothiazol-2-yl-3-chloro-4-substituted-azetidin-2-ones. Arzneimittelforschung. 2011;53:640–7.
Anand M, Selvaraj V, Alagar M. Synthesis, characterization and evaluation of antioxidant and anticancer activities of novel benzisoxazole-substituted-allyl derivatives. Korean J Chem Eng. 2014;31:659–63.
Chandra S, Mahadimane V. Effect of novel benzisoxazole derivatives against ehrlich ascites carcinoma cells in swiss albino mice: cytotoxic and haematalogical studies. Int J Pharma Sci Res. 2015;6:3606–11.
Jain M, Kwon CH. 1,2-Benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. J Med Chem. 2003;46:5428–36.
Ashwini N, Garg M, Mohan CD, et al. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation. Bioorg Med Chem. 2015;23:6157–65.
Aiello S, Wells G, Stone EL, et al. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5- fluorobenzothiazole (PMX 610, NSC 721648). J Med Chem. 2008;51:5135–9.
Rakesh KP, Shantharam CS, Sridhara MB, et al. Benzisoxazole: a privileged scaffold for medicinal chemistry. Med Chem Commun. 2017;8:2023–39.
Purohit SS, VeerapurV P. Benzisoxazole containing thiazolidinediones as peroxisome proliferator activated receptor-γ agonists: design, molecular docking, synthesis & antidiabetic studies. Sch Acad J Pharm. 2014;3:26–37.
Sills GJ. Zonisamide. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. University of Liverpool, Liverpool, United Kingdom, Elsevier. 2009; p1–6.
Vasquez AR, Bobo WV. Mood stabilizers: risperidone for treating bipolar disorders in adults. In: Riederer P, Laux G, Mulsant B, Le W, Nagatsu T, editors. NeuroPsychopharmacotherapy. Cham: Springer; 2020; pp1–32.
Green B. Paliperidone: a clinical review. Curr Drug Ther. 2009;4:7–11.
Weiden P. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6:34–44.
Uto Y. 1,2-Benzisoxazole compounds: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015; 25(6): 643–662.
Deering RW, Whalen KE, Alvarez I, et al. Identification of a bacteria-produced benzisoxazole with antibiotic activity against multi-drug resistant Acinetobacter baumannii. J Antibiot (Tokyo). 2021;74(6):370–80.
Giacomini E, Rupiani S, Guidotti L, et al. The use of stilbene scaffold in medicinal chemistry and multi- target drug design. Curr Med Chem. 2016;23(23):2439–89.
De Filippis B, Ammazzalorso A, Fantacuzzi M, et al. Anticancer activity of stilbene-based derivatives. ChemMedChem. 2017;12(8):558–70.
Rauf A, Imran M, Butt MS, et al. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr. 2018;58(9):1428–47.
Dyck GJB, Raj P, Zieroth S, et al. The effects of resveratrol in patients with cardiovascular disease and heart failure: A narrative review. Int J Mol Sci. 2019;20(4):904.
Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients. 2016;8(5):250.
Komorowska J, Wątroba M, Szukiewicz D. Review of beneficial effects of resveratrol in neurodegenerative diseases such as Alzheimer’s disease. Adv Med Sci. 2020;65(2):415–23.
De Filippis B, Ammazzalorso A, Amoroso R, et al. Stilbene derivatives as new perspective in antifungal medicinal chemistry. Drug Dev Res. 2019;80(3):285–93.
Chaudhary A, Pandeya SN, Kumar P, et al. Combretastatin a-4 analogs as anticancer agents. Mini Rev Med Chem. 2007;7(12):1186–205.
McCormack D, McFadden D. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482.
McCormack D, McFadden D. Pterostilbene and cancer: current review. J Surg Res. 2012;173(2):e53–61.
Kershaw J, Kim KH. The therapeutic potential of piceatannol, a Natural stilbene, in metabolic diseases: A review. J Med Food. 2017;20(5):427–38.
Banik K, Ranaware AM, Harsha C, et al. Piceatannol: A natural stilbene for the prevention and treatment of cancer. Pharmacol Res. 2020;153:104635.
Morphy R, Rankovic Z. Design of multitarget ligands. In: Rankovic Z, Morphy R, editors. Lead generation approaches in drug discovery. Hoboken: Wiley; 2010. p. 141–64.
Morphy R, Rankovic Z. Designing multiple ligands—medicinal chemistry strategies and challenges. Curr Pharm Des. 2009;15(6):587–600.
Bérubé G. An overview of molecular hybrids in drug discovery. Expert Opin Drug Discov. 2016;11(3):281–305.
Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem. 2006;49(16):4961–70.
Decker M. Design of hybrid molecules for drug development. Amsterdam: Elsevier; 2017.
Das N, Dhanawat M, Dash B, et al. Codrug: an efficient approach for drug optimization. Eur J Pharm Sci. 2010;41(5):571–88.
Vu CB, Bemis JE, Benson E, et al. Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid. J Med Chem. 2016;5(3):1217–31.
Fornasari E, Di Stefano A, Cacciatore I. Direct-and spacer-coupled codrug strategies for the treatment of Alzheimer’s disease. Austin Alzheimers J Parkinsons Dis. 2014;1(2):9.
Poudel YB, Chowdari NS, Cheng H, et al. Chemical modification of linkers provides stable linker-payloads for the generation of antibody-drug conjugates. ACS Med Chem Lett. 2020;11(11):2190–4.
Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol. 2015;6:205.
Hopkins AL, Keserü GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13:105–21.
Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res. 2008;41(1):69–77.
Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today. 2007;12(1-2):34–42.
Kabir MT, Uddin MS, Mamun AA, et al. Combination drug therapy for the management of Alzheimer’s disease. Int J Mol Sci. 2020;21(9):3272.
Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.
Kabir MT, Abu Sufian M, Uddin MS, et al. NMDA receptor antagonists: Repositioning of memantine as multitargeting agent for Alzheimer’s therapy. Curr Pharm Des. 2019;25:3506–18.
Uddin MS, Kabir MT, Tewari D, et al. Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer’s disease. Sci Total Environ. 2020;700:1–11.
Kabir MT, Uddin MS, Begum MM, et al. Cholinesterase inhibitors for Alzheimer’s disease: Multitargeting strategy based on anti-Alzheimer’s drugs repositioning. Curr Pharm Des. 2019;25:3519–35.
Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des Devel Ther. 2016;10:3267–79.
Agatonovic-Kustrin S, Kettle C, Morton DW. A molecular approach in drug development for Alzheimer’s disease. Biomed Pharmacother. 2018;106:553–65.
Capurro V, Busquet P, Lopes JP, et al. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer’s disease. PLoS ONE. 2013;8:e56870.
Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24:358–69.
Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging. 2011;28:539–46.
Posadas I, Lopez-Hernandez B, Cena V. Nicotinic receptors in neurodegeneration. Curr Neuropharmacol. 2013;11:298–314.
Jun Kawamata J, Syuuichirou SS, Shun SS. α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson’s disease. Curr Drug Targets. 2012;13:623–30.
Takada-Takatori Y, Kume T, Sugimoto M, et al. Acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006;51:474–86.
Lopes JP, Tarozzo G, Reggiani A, et al. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav. 2013;3:67–74.
Rosini M, Simoni E, Bartolini M, et al. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: A promising direction for the multi-target-directed ligands gold rush. J Med Chem. 2008;51:4381–4.
Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer’s disease. J Med Chem. 2012;55:9708–21.
Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov. 2006;5:160–70.
Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364:626–32.
Tsiailanis A, Tsoumani M, Stylos EK, et al. Designing natural product hybrids bearing triple antiplatelet profile and evaluating their human plasma stability. Methods Mol Biol. 2018;1824:371–85.
Alam MM, Hassan AHE, Kwon YH, et al. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. Arch Pharm Res. 2018;41(1):35–45.
Price AJ, Howard S, Cons BD. Fragment-based drug discovery and its application to challenging drug targets. Essays in Biochem. 2017;61(5):475–84.
Tounge BA, Parker MH. Designing a diverse high-quality library for crystallography-based FBDD screening. Fragment-based drug design—Tools, practical approaches, and examples. Methods in Enzymol. 2011;493:3–20.
Li Q. Application of fragment-based drug discovery to versatile targets. Front Mol Biosci. 2020;7:180.
Doak BC, Norton RS, Scanlon MJ. The ways and means of fragment-based drug design. Pharmacol Therapeut. 2016;167:28–37.
Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem. 2009;1:187–92.
Erlanson DA, Fesik SW, Hubbard RE, et al. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016;15:605–19.
Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596.
Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discovery. 2012;11:873.
Erlanson DA. Introduction to fragment-based drug discovery. In Fragment-Based Drug Discovery and X-Ray Crystallography. Davies TG, Hyvönen M (eds). Springer-Verlag, Berlin. 2012; pp1–32.
Jacquemard C, Kellenberger E. A bright future for fragment-based drug discovery: What does it hold? Exp Opin Drug Discov. 2019;14:413–6.
Whittaker M, Law RJ, Ichihara O, et al. Fragments: past, present and future. Drug Discov Today. 2010;7:e163–71.
Aretz J, Kondoh Y, Honda K, et al. Chemical fragment arrays for rapid druggability assessment. Chem Commun. 2016;52:9067–70.
Gee CT, Arntson KE, Urick AK, et al. Protein-observed 19F-NMR for fragment screening, affinity quantification and druggability assessment. Nat Protoc. 2016;11:1414.
Dang CV, Reddy EP, Shokat KM, et al. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017;17:502–8.
Owens J. Determining druggability. Nat Rev Drug Discov. 2007;6:187.
Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007;25:71–5.
Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21:1102–14.
Erlanson DA. Fragment-based lead discovery: a chemical update. Curr Opin Biotechnol. 2006;17:643–52.
Lamoree B, Hubbard RE. Current perspectives in fragment-based lead discovery (FBLD). Essays Biochem. 2017;61:453–64.
Brunst S, Kramer JS, Kilu W, et al. Systematic assessment of fragment identification for multitarget drug design. ChemMedChem. 2021;16(7):1088–92.
Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discovery Today. 2007;12:156–60.
Bottegoni G, Favia AD, Recanatini M, et al. The role of fragment-based and computational methods in polypharmacology. Drug Discovery Today. 2012;17:23–34.
Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009;52(2):379–88.
Speck-Planche A, Kleandrova VV, Luan F, et al. Multi-target inhibitors for proteins associated with Alzheimer: in silico discovery using fragment-based descriptors. Curr Alzheimer Res. 2013;10(2):117–24.
Speck-Planche A, Cordeiro MNDS. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins. Mol Divers. 2017;21(3):511–23.
Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts. Adv Drug Deliv Rev. 2016;101:108–21.
Yang J, Kopeček J. Macromolecular therapeutics. J Control Release. 2014; 0: 288–303.
Rütter M, Milošević N, David A. Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs. J Control Release. 2021;330:1191–207.
Ramsay RR, Popovic-Nikolic MR, Nikolic K, et al. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7:3.
Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26.
Raju TS, Strohl WR. Potential therapeutic roles for antibody mixtures. Expert Opin Biol Ther. 2013;13(10):1347–52.
Jakob CG, Edalji R, Judge RA, et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs. 2013;5:358–63.
Günther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy (Alphaglobin®/Flebogamma®) in secondary immunodeficiency with recurrent serious bacterial infections. Microbiol Immunol. 2013;57(7):527–35.
Meng Q, Garcia-Rodriguez C, Manzanarez G, et al. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012;430:141–50.
Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov Today. 2006;11:655–60.
Strohl WR, Strohl LM. Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharma industry. Woodhead Publishing Series in Biomedicine No. 11 Woodhead Publishing; Cambridge. 2012.
Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res. 2011;17:5962–72.
Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA. 2013;110:5145–50.
Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608.
Shin SU. Chimeric antibody: potential applications for drug delivery and immunotherapy. Biotherapy. 1991;3(1):43–53.
Wright A, Shin SU, Morrison SL. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol. 1992;12(3-4):125–68.
Panowski S, Bhakta S, Raab H, et al. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34–45.
Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: A comprehensive review. Mol Cancer Res. 2020;18(1):3–19.
Hamilton GS. Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of develo** drug-biologic hybrids. Biologicals. 2015;43(5):318–32.
Fitzpatrick-Dimond PF. Antibody-drug conjugates stage a comeback. GEN: Genetic Engineering and Biotechnology News. 2010.
DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.
Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329–32.
Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Can Res. 1992;52(1):127–31.
Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.
Damelin M, Zhong W, Myers J, et al. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32:3494–507.
Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Can. 2016;114:362–7.
Tipton TR, Roghanian A, Oldham RJ, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015;125:1901–9.
Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. mAbs. 2016;8:659–71.
Casi G, Neri D. Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm. 2015;12:1880–4.
Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Can Lett. 2007;255(2):232–40.
Bąchor R, Kluczyk A, Stefanowicz P, et al. New method of peptide cleavage based on Edman degradation. Mol Divers. 2013;17(3):605–11.
Axup JY, Bajjuri KM, Ritland M, et al. (October 2012). Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Nat Acad Sci U S A. 109 (40): 16101–16106.
Lyon RP, Setter JR, Bovee TD, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol. 2014;32(10):1059–62.
Kolodych S, Koniev O, Baatarkhuu Z, et al. CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability. Bioconjugate Chem. 2015;26(2):197–200.
Wulbrand C, Seidl C, Gaertner FC, et al. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLOS ONE. 2013;8(5):e64730.
Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Medicinal Chem. 2012;19(19):3103–27.
Dovgan I, Koniev O, Kolodych S, et al. Antibody-oligonucleotide conjugates as therapeutic, imaging, and detection agents. Bioconjugate Chem. 2019;30(10):2483–501.
Walsh SJ, Bargh JD, Dannheim FM, et al. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev. 2021;50(2):1305–53.
Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101–6.
Schumacher D, Hackenberger CP, Leonhardt H, et al. Current status: Site-specific antibody drug conjugates. J Clin Immunol. 2016;36(Suppl 1):100–7.
Sochaj AM, Świderska KW, Otlewski J. Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol Adv. 2015;33(6 Pt 1):775–84.
Hussain AF, Grimm A, Sheng W, et al. Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches. Pharmaceuticals (Basel). 2021;14(4):343.
Chernikov IV, Vlassov VV, Chernolovskaya EL. Current development of siRNA bioconjugates: From research to the clinic. Front Pharmacol. 2019;10:444.
**a CF, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm. 2009;6:747–51.
Ma Y, Kowolik CM, Swiderski PM, et al. Humanized Lewis-Y specific antibody-based delivery of STAT3 siRNA. ACS Chem Biol. 2011;6:962–70.
Sugo T, Terada M, Oikawa T, et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release. 2016;237:1–13.
Ibtehaj N, Huda R. High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model. Clin Immunol. 2017;176:122–30.
Cuellar TL, Barnes D, Nelson C, et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 2014;43:1189–203.
Inumaru S. Introduction to advanced biologics. Vet Immunol Immunopathol. 2012;148(1-2):126–8.
Lacaná E, Amur S, Mummanneni P, et al. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther. 2007;82(4):466–71.
O’Neill ID, Scully C. Biologics in oral medicine: principles of use and practical considerations. Oral Dis. 2012;18(6):525–36.
Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics. Clin Pharmacokinet. 2003;42:1089–105.
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986;46:6387–92.
Kopeček J. Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev. 2013;65:49–59.
Seymour LW, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34:1629–36.
Chipman SD, Oldham FB, Pezzoni G, Singer JW. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine. 2006;1:375–83.
Weiss GJ, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013;31:986–1000.
Yurkovetskiy AV, Fram RJ. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev. 2009;61:1193–202.
Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm Res. 2006;23:1417–50.
Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev. 2009;61:1117–20.
Destouches D, Page N, Hamma-Kourbali Y, et al. A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 2011;71:3296–305.
Zhang Z, et al. DNA-scaffolded multivalent ligands to modulate cell function. Chembiochem. 2014;15:1268–73.
Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol. 2000;4:696–703.
Stephens B, Handel TM. Chemokine receptor oligomerization and allostery. Prog Mol Biol Transl Sci. 2013;115:375–420.
Ljubimova JY, Fujita M, Ljubimov AV, et al. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond). 2008;3(2):247–65.
Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–84.
Li L, Yang J, Wang J, et al. Drug-free macromolecular therapeutics exhibit amplified apoptosis in G2/M phase arrested cells J Drug Target. 2019; 27(5-6): 566–72.
Chu TW, Kopeček J. drug-free macromolecular therapeutics--a new paradigm in polymeric nanomedicines. Biomater Sci. 2015; 3(7): 908–922.
Tavares MR, Pechar M, Chytil P, et al. Polymer-based drug-free therapeutics for anticancer, anti-inflammatory, and antibacterial treatment. Macromol Biosci. 2021;21(8):e2100135.
Wu K, Liu J, Johnson RN, et al. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed. 2010;49:1451–5.
Ho TT, Tran QT, Chai CL. The polypharmacology of natural products. Future Med Chem. 2018;10(11):1361–8.
Fang J, Liu C, Wang Q, et al. In silico polypharmacology of natural products. Brief Bioinform. 2018;19(6):1153–71.
Kibble M, Saarinen N, Tang J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32(8):1249–66.
Butler MS, Robertson AA, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014;31:1612–61.
Shen B. A new golden age of natural products drug discovery. Cell. 2015;163:1297–300.
Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 2011;11:211–8.
Fang J, Cai C, Wang Q, et al. Systems pharmacology-based discovery of natural products for precision oncology through targeting cancer mutated genes. CPT Pharmacometrics Syst Pharmacol. 2017;6:177–87.
Gu J, Gui Y, Chen L, et al. Use of natural products as chemical library for drug discovery and network pharmacology. PLoS One. 2013;8(4):e62839.
Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol. 2007;25:1119–26.
Barneh F, Jafari M, Mirzaie M. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. Brief Bioinform. 2016;17:1070–80.
Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014;42:D1083–90.
Wang Y, Bolton E, Dracheva S, et al. An overview of the PubChem BioAssay resource. Nucleic Acids Res. 2010;38:D255–66.
Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091–7.
Yang H, Qin C, Li YH, et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 2016;44:D1069–74.
Wagner AH, Coffman AC, Ainscough BJ, et al. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016;44:D1036–44.
Kuhn M, Szklarczyk D, Pletscher-Frankild S, et al. STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res. 2014;42:D401–7.
Nickel J, Gohlke BO, Erehman J, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42:W26–31.
Ye H, Ye L, Kang H, et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 2011;39:D1055–9.
Xue R, Fang Z, Zhang M, et al. TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res. 2013;41:D1089–95.
Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
Mangal M, Sagar P, Singh H, et al. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41:D1124–9.
Tao W, Li B, Gao S, et al. CancerHSP: anticancer herbs database of systems pharmacology. Sci Rep. 2015;5:11481.
Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet. 2004;5:262–75.
Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.
Duan Q, Flynn C, Niepel M, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014;42:W449–60.
Igarashi Y, Nakatsu N, Yamashita T, et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 2015;43:D921–7.
Ganter B, Snyder RD, Halbert DN, et al. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. Pharmacogenomics. 2006;7:1025–44.
Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Can. 2007;7:54–60.
Adams JU. Genetics: big hopes for big data. Nature. 2015;527:S108–9.
Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 2015;43:D470–8.
Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database–2009 update. Nucleic Acids Res. 2009;37:D767–72.
Mosca R, Ceol A, Aloy P. Interactome3D: adding structural details to protein networks. Nat Methods. 2013;10:47–53.
Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362–8.
Licata L, Briganti L, Peluso D, et al. MINT, themolecular interaction database: 2012 update. Nucleic Acids Res. 2012;40:D857–61.
Cheng F, Jia P, Wang Q, et al. Quantitative network map** of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget. 2014;5:3697–710.
Cheng F, Murray JL, Zhao J, et al. Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis. PLoS Comput Biol. 2016;12:e1005074.
Cheng F, Liu C, Shen B, et al. Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Syst Biol. 2016;10(Suppl 3):65.
Cheng F, Jia P, Wang Q, et al. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol. 2014;31:2156–69.
Chen X, Yan CC, Zhang X, et al. Drug-target interaction prediction: databases, web servers and computational models. Brief Bioinform. 2016;17:696–712.
Koutsoukas A, Simms B, Kirchmair J, et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics. 2011;74:2554–74.
Yue R, Shan L, Yang X, et al. Approaches to target profiling of natural products. Curr Med Chem. 2012;19:3841–55.
Jenkins JL, Bender A, Davies JW. In silico target fishing: predicting biological targets from chemical structure. Drug Discov Today Technol. 2007;3:413–21.
Harren J, Andrew RL. Structure-based Drug Discovery. Dordrecht: Netherlands, Springer; 2007.
Taboureau O, Baell JB, Fernandez-Recio J, et al. Established and emerging trends in computational drug discovery in the structural genomics era. Chem Biol. 2012;19:29–41.
Luo H, Mattes W, Mendrick DL, et al. Molecular docking for identification of potential targets for drug repurposing. Curr Top Med Chem. 2016;16:3636–45.
Ye H, Wei J, Tang K, et al. Drug repositioning through network pharmacology. Curr Top Med Chem. 2016;16:3646–56.
Sakkiah S, Ng HW, Tong W, et al. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery. Expert Opin Ther Targets. 2016;20:1267–82.
Liu LJ, Leung KH, Chan DS, et al. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis. 2014;5:e1293.
Zhong HJ, Lee BR, Boyle JW, et al. Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction. Chem Commun. 2016;52:5788–91.
Singh T, Gupta NA, Xu S, et al. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor. Oncotarget. 2015;6:21268–82.
Zhong HJ, Ma VP, Cheng Z, et al. Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. Biochimie. 2012;94:2457–60.
Lee HM, Chan DS, Yang F, et al. Identification of natural product fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening. Chem Commun. 2010;46:4680–2.
Ma D-L, Chan DS-H, Leung C-H. Molecular docking for virtual screening of natural product databases. ChemSci. 2011;2:1656–65.
Cierpicki T, Grembecka J. Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem. 2014;6:447–62.
Chen YZ, Zhi DG. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins. 2001;43:217–26.
Wang JC, Chu PY, Chen CM, et al. idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucleic Acids Res. 2012;40:W393–9.
Lauro G, Romano A, Riccio R, et al. Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. J Nat Prod. 2011;74:1401–7.
Lauro G, Masullo M, Piacente S, et al. Inverse virtual screening allows the discovery of the biological activity of natural compounds. Bioorg Med Chem. 2012;20:3596–602.
Vuong H, Cheng F, Lin CC, et al. Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med. 2014;6:81.
Zhao J, Cheng F, Wang Y, et al. Systematic prioritization of druggable mutations in approximately 5000 genomes across 16 cancer types using a structural genomics-based approach. Mol Cell Proteomics. 2016;15:642–56.
Lu W, Cheng F, Jiang J, et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci Rep. 2015;5:8114.
Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discovery. Pharmacol Rev. 2014;66:334–95.
Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today. 2015;20:318–31.
Yan X, Liao C, Liu Z, et al. Chemical structure similarity search for ligand-based virtual screening: methods and computational resources. Curr Drug Targets. 2016;17:1580–5.
Liu X, Ouyang S, Yu B, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore map** approach. Nucleic Acids Res. 2010;38:W609–14.
Yan X, Li J, Liu Z, et al. Enhancing molecular shape comparison by weighted Gaussian functions. J Chem Inf Model. 2013;53:1967–78.
Fang J, Yang R, Gao L, et al. Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery. J Chem Inf Model. 2013;53:3009–20.
Fang J, Yang R, Gao L, et al. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery. Mol Divers. 2015;19:149–62.
Fang J, Li Y, Liu R, et al. Discovery of multitarget-directed ligands against Alzheimer’s disease through systematic prediction of chemical-protein interactions. J Chem Inf Model. 2015;55:149–64.
Fang J, Pang X, Wu P, et al. Discovery of neuroprotective compounds by machine learning approaches. RSC Adv. 2016;6:9857.
Cheng F, Li W, Liu G, et al. In silico ADMET prediction: recent advances, current challenges and future trends. Curr Top Med Chem. 2013;13:1273–89.
Sprague B, Shi Q, Kim MT, et al. Design, synthesis and experimental validation of novel potential chemopreventive agents using random forest and support vector machine binary classifiers. J Comput Aided Mol Des. 2014;28:631–46.
Bilsland AE, Pugliese A, Liu Y, et al. Identification of a selective G1-phase benzimidazolone inhibitor by a senescence-targeted virtual screen using artificial neural networks. Neoplasia. 2015;17:704–15.
Liu H, Sun J, Guan J, et al. Improving compound-protein interaction prediction by building up highly credible negative samples. Bioinformatics. 2015;31:i221–9.
Mousavian Z, Masoudi-Nejad A. Drug-target interaction prediction via chemogenomic space: learning-based methods. Expert Opin Drug Metab Toxicol. 2014;10:1273–87.
Yamanishi Y. Chemogenomic approaches to infer drug-target interaction networks. Methods Mol Biol. 2013;939:97–113.
Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One. 2010;5:e11764.
Yamanishi Y, Araki M, Gutteridge A, et al. Prediction of drug target interaction networks from the integration of chemical and genomic spaces. Bioinformatics. 2008;24:i232–40.
Bleakley K, Yamanishi Y. Supervised prediction of drug target interactions using bipartite local models. Bioinformatics. 2009;25:2397–403.
Keum J, Yoo S, Lee D, et al. Prediction of compound-target interactions of natural products using large-scale drug and protein information. BMC Bioinformatics. 2016;17(Suppl 6):219.
Yu H, Chen J, Xu X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One. 2012;7:e37608.
Huang C, Zheng C, Li Y, et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform. 2014;15:710–33.
Sawada R, Kotera M, Yamanishi Y. Benchmarking a wide range of chemical descriptors for drug-target interaction prediction using a chemogenomic approach. Mol Inform. 2014;33:719–31.
Cheng F, Zhou Y, Li J, et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst. 2012;8:2373–84.
Cheng F, Zhou Y, Li W, et al. Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One. 2012;7:e41064.
Wu Z, Cheng F, Li J, et al. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning. Brief Bioinform. 2017;18:333–47.
Wu Z, Lu W, Wu D, et al. In silico prediction of chemical mechanism of action via an improved network-based inference method. Br J Pharmacol. 2016;173:3372–85.
Cheng F, LiW ZY, et al. Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic derived models (PTDMs). Mol Biosyst. 2013;9:1316–25.
Li J, Wu Z, Cheng F, et al. Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology. Sci Rep. 2014;4:5576.
Li J, Lei K, Wu Z, et al. Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget. 2016;7:45584–96.
Kitano H. Systems biology: a brief overview. Science. 2002;295:1662–4.
Kitano H. Computational systems biology. Nature. 2002;420:206–10.
Berg EL. Systems biology in drug discovery and development. Drug Discov Today. 2014;19:113–25.
Cheng F, Murray JL, Rubin DH. Drug repurposing: new treatments for Zika virus infection? Trends Mol Med. 2016;22:919–21.
Qu XA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today. 2012;17:1289–98.
Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321–30.
Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331–42.
Langley SR, Dwyer J, Drozdov I, et al. Proteomics: from single molecules to biological pathways. Cardiovasc Res. 2013;97:612–22.
Bensimon A, Heck AJ, Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012;81:379–405.
Savitski MM, Reinhard FB, Franken H, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.
Franken H, Mathieson T, Childs D, et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015;10:1567–93.
Reinhard FB, Eberhard D. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat Methods. 2015;12:1129–31.
Sacco F, Silvestri A, Posca D, et al. Deep proteomics of breast cancer cells reveals that metformin rewires signaling networks away from a pro-growth state. Cell Syst. 2016;2:159–71.
Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14:111–29.
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–83.
Birkenstock T, Liebeke M, Winstel V, et al. Exometabolome analysis identifies pyruvate dehydrogenase as a target for the antibiotic triphenylbismuthdichloride in multiresistant bacterial pathogens. J Biol Chem. 2012;287:2887–95.
Zhang B, Watts KM, Hodge D, et al. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry. 2011;50:3570–7.
Bayet-Robert M, Lim S, Barthomeuf C, et al. Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics. Biochem Pharmacol. 2010;80:1170–9.
Pulido MR, Garcia-Quintanilla M, Gil-Marques ML, et al. Identifying targets for antibiotic development using omics technologies. Drug Discov Today. 2016;21:465–72.
Zhao Y, Hu Q, Cheng F, et al. SoNar, a highly responsive NADþ/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab. 2015;21:777–89.
Kim HK, Wilson EG, Choi YH, et al. Metabolomics: a tool for anticancer lead-finding from natural products. Planta Med. 2010;76:1094–102.
Collins GS, de Groot JA, Dutton S, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14:40.
Reker D, Perna AM, Rodrigues T, et al. Revealing the macromolecular targets of complex natural products. Nat Chem. 2014;6(12):1072–8.
Ashburn TT, Thor KB. Drug repositioning: identifying and develo** new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
Schcolnik-Cabrera A, Juárez-López D, Duenas-Gonzalez A. Perspectives on drug repurposing. Curr Med Chem. 2021;28(11):2085–99.
Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharmaceutical Med. 2012;24(3):151–9.
Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–80.
Sam E, Athri P. Web-based drug repurposing tools: a survey. Brief Bioinform. 2019;20(1):299–316.
Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, et al. Drug databases and their contributions to drug repurposing Genomics. 2020; 112(2): 1087–1095.
Karaman B, Sippl W. Computational drug repurposing: Current trends. Curr Med Chem. 2019;26(28):5389–409.
Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today. 2011;8(3-4):61–9.
Haupt VJ, Daminelli S, Schroeder M. Drug promiscuity in PDB: Protein binding site similarity is key. PLoS One. 2013;8(6):e65894.
Feldmann C, Miljković F, Yonchev D, et al. Identifying promiscuous compounds with activity against different target classes. Molecules. 2019;24(22):4185.
Gupta MN, Alam A, Hasnain SE. Protein promiscuity in drug discovery, drug-repurposing and antibiotic resistance. Biochimie. 2020;175:50–7.
Gilberg E, Gütschow M, Bajorath J. Promiscuous ligands from experimentally determined structures, binding conformations, and protein family-dependent interaction hotspots. ACS Omega. 2019;4(1):1729–37.
Irwin JJ, Duan D, Torosyan H, et al. An aggregation advisor for ligand discovery. J Med Chem. 2015;58:7076–87.
Baell JB, Walters MA. Chemistry: Chemical con artists foil drug discovery. Nature. 2014;513:481–3.
Aldrich C, Bertozzi C, Georg GI, et al. The ecstasy and agony of assay interference compounds. J Chem Inf Model. 2017;57:387–90.
Stumpfe D, Tinivella A, Rastelli G, et al. Promiscuity of inhibitors of human protein kinases at varying data confidence levels and test frequencies. RSC Adv. 2017;7:41265–71.
Hu Y, Bajorath J. Entering the ‘big data’ era in medicinal chemistry: Molecular promiscuity analysis revisited. Future Sci OA. 2017;3:FSO179.
Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299:211–3.
Schuster D, Laggner C, Langer T. Why drugs fail—a study on side effects in new chemical entities. Curr Pharm Des. 2005;11:3545–59.
Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419–24.
Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg. 2011;8:61–9.
Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J. 2012;14:759–63.
Gallo K, Goede A, Eckert A, et al. PROMISCUOUS 2.0: a resource for drug-repositioning. Nucleic Acids Res. 2021;49(D1):D1373–80.
Xue H, Li J, **e H, et al. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14:1232–44.
Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–19.
Eder J, Sedrani R, Wiesmann C. The discovery of first-in class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13:577–87.
Horvath P, Aulner N, Bickle M, et al. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016;15:715–69.
Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 2011;63:411–36.
Sanseau P, Agarwal P, Barnes MR, et al. Use of genome-wide association studies. Nat Biotechnol. 2012;30:317–20.
Rastegar-Mojarad M, Zhan Y, Kolesar JM, et al. Opportunities for drug repositioning from phenome-wide association studies. Nat Biotechnol. 2015;33:342–5.
Iorio F, Rittman T, Ge H, et al. Transcriptional data: a new gateway to drug repositioning? Drug Discov Today. 2013;18:350–7.
Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;3:96ra77.
Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112:2020–3.
Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 2015;3:2–19.
Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975–87.
Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.
Fowler KD, Funt JM, Artyomov MN, et al. Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets. Sci Rep. 2015;5:14324–32.
Xu H, Aldrich MC, Chen Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2014;22:179–91.
Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS One. 2011;6:e28025.
Kuhn M. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075–9.
Gottlieb A, Stein GY, Ruppin ER, et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011;7:496–505.
Yu L, Ma X, Zhang L, et al. Prediction of new drug indications based on clinical data and network modularity. Sci Rep. 2016;6:32530.
Tan F, Yang R, Xu X, et al. Drug repositioning by applying ‘expression profiles’ generated by integrating chemical structure similarity and gene semantic similarity. Mol Biosyst. 2014;10:1126–38.
Paik H, Chung AY, Park HC, et al. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. Sci Rep. 2015;5:8580–8.
Shameer K, Glicksberg BS, Hodos R, et al. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Brief Bioinform. 2018;19:656–78.
Brown AS, Patel CJ. A standard database for drug repositioning. Sci Data. 2017;4:170029.
Zhao C, Dai X, Li Y, et al. EK-DRD: a comprehensive database for drug repositioning inspired by experimental knowledge. J Chem Inf Model. 2019;59:3619–24.
Wu H, Huang J, Zhong Y, et al. DrugSig: A resource for computational drug repositioning utilizing gene expression signatures. PLoS One. 2017;12:e0177743.
Avram S, Bologa CG, Holmes J, et al. DrugCentral 2021 supports drug discovery and repositioning. Nucleic Acids Res. 2021;49(D1):D1160–9.
Ursu O, Holmes J, Knockel J, et al. DrugCentral: Online drug compendium. Nucleic Acids Res. 2017;45:D932–9.
UniProtConsortium UniProt. a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–15.
Hastings J, Owen G, Dekker A, et al. ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res. 2016;44:D1214–9.
Himmelstein DS, Lizee A, Hessler C, et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife. 2017;6:e26726.
Aguirre-Plans J, Piñero J, Sanz F, et al. GUILDify v2.0: A tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets. J Mol Biol. 2019;431:2477–84.
Chambers J, Davies M, Gaulton A, et al. UniChem: a unified chemical structure cross-referencing and identifier tracking system. J Cheminform. 2013;5:3.
Alexander SPH, Kelly E, Mathie A, et al. The concise guide to pharmacology 2019/20: Introduction and other protein targets. Br J Pharmacol. 2019;176:S1–20.
Brown AS, Patel CJ. A standard database for drug repositioning. Scientific Data. 2017;4:170029.
Mayers M, Li TS, Queralt-Rosinach N, et al. Time-resolved evaluation of compound repositioning predictions on a text-mined knowledge network. BMC Bioinformatics. 2019;20:653.
Wu Q, Taboureau O, Audouze K. Development of an adverse drug event network to predict drug toxicity. Curr Res Toxicol. 2020;1:48–55.
Ursu O, Holmes J, Bologa CG, et al. DrugCentral 2018: an update. Nucleic Acids Res. 2019;47:D963–70.
Levin JM, Oprea TI, Davidovich S, et al. Artificial intelligence, drug repurposing and peer review. Nat Biotechnol. 2020;38:1127–31.
Avram S, Curpan R, Halip L, et al. Off-patent drug repositioning. J Chem Inf Model. 2020;60(12):5746–53.
KC G, Bocci G, Verma S, et al. REDIAL-2020: A suite of machine learning models to estimate anti-SARS-CoV-2 activities. ChemRxiv. 2020.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wang, Z., Yang, B. (2022). Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs. In: Polypharmacology. Springer, Cham. https://doi.org/10.1007/978-3-031-04998-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-04998-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-04997-2
Online ISBN: 978-3-031-04998-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)